Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1583404,steady state antigen concentration,Pharmacokinetics of the rt-PA showed a steady state antigen concentration of 240 ng/ml and activity of 200 IU/ml during the initial 2-hour infusion and a postinfusion half-life of 5 minutes.,Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1583404/),[ng] / [ml],240,4623,DB00009,Alteplase
,1583404,activity,Pharmacokinetics of the rt-PA showed a steady state antigen concentration of 240 ng/ml and activity of 200 IU/ml during the initial 2-hour infusion and a postinfusion half-life of 5 minutes.,Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1583404/),[iu] / [ml],200,4624,DB00009,Alteplase
,1583404,half-life,Pharmacokinetics of the rt-PA showed a steady state antigen concentration of 240 ng/ml and activity of 200 IU/ml during the initial 2-hour infusion and a postinfusion half-life of 5 minutes.,Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1583404/),min,5,4625,DB00009,Alteplase
,12177691,K(i),"DPC423, 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, is a synthetic, orally bioavailable, competitive, and selective inhibitor of human coagulation factor Xa (K(i) [nM]: factor Xa, 0.15; trypsin, 60; thrombin, 6000; plasma kallikrein, 61; activated protein C, 1800; factor IXa, 2200; factor VIIa, >15,000; chymotrypsin, >17,000; urokinase, >19,000; plasmin, >35,000; tissue plasminogen activator, >45,000; complement factor I, 44,000 [IC(50)]).","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),nM,0.15,7185,DB00009,Alteplase
,12177691,K(i),"DPC423, 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, is a synthetic, orally bioavailable, competitive, and selective inhibitor of human coagulation factor Xa (K(i) [nM]: factor Xa, 0.15; trypsin, 60; thrombin, 6000; plasma kallikrein, 61; activated protein C, 1800; factor IXa, 2200; factor VIIa, >15,000; chymotrypsin, >17,000; urokinase, >19,000; plasmin, >35,000; tissue plasminogen activator, >45,000; complement factor I, 44,000 [IC(50)]).","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),nM,44,7186,DB00009,Alteplase
,12177691,oral bioavailability,"In dogs, DPC423 had a good pharmacokinetic profile with an oral bioavailability of 57%, a plasma clearance of 0.24 L/kg/h, and a plasma half-life of 7.5 h.","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),%,57,7187,DB00009,Alteplase
,12177691,plasma clearance,"In dogs, DPC423 had a good pharmacokinetic profile with an oral bioavailability of 57%, a plasma clearance of 0.24 L/kg/h, and a plasma half-life of 7.5 h.","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),[l] / [h·kg],0.24,7188,DB00009,Alteplase
,12177691,plasma half-life,"In dogs, DPC423 had a good pharmacokinetic profile with an oral bioavailability of 57%, a plasma clearance of 0.24 L/kg/h, and a plasma half-life of 7.5 h.","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),h,7.5,7189,DB00009,Alteplase
,12177691,IC(50),"In rabbit and rat models of arteriovenous shunt thrombosis, DPC423 was an effective antithrombotic agent with an IC(50) of 150 and 470 nM, respectively.","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),nM,150,7190,DB00009,Alteplase
,12177691,IC(50),"In rabbit and rat models of arteriovenous shunt thrombosis, DPC423 was an effective antithrombotic agent with an IC(50) of 150 and 470 nM, respectively.","Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177691/),nM,470,7191,DB00009,Alteplase
,20813398,FCL,FCL for control clots was 14% (95% Confidence Interval: 13-15%).,"Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20813398/),%,14,8988,DB00009,Alteplase
,20813398,FCL,"Here, FCL was 43% (36-51) and 35% (32-38) respectively.","Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20813398/),%,43,8989,DB00009,Alteplase
,20813398,FCL,"Here, FCL was 43% (36-51) and 35% (32-38) respectively.","Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20813398/),%,35,8990,DB00009,Alteplase
,3612530,alpha T1/2,"After bolus i.v. injection in rabbits with 2.5 kg. b.wt., the disappearance rate of all three forms from plasma could be described by a two-compartment disposition model with the following pharmacokinetic parameters: alpha T1/2, 3.2 to 3.9 min; beta T1/2, 15 to 16 min; volume of the central compartment, 170 to 200 ml; total volume of distribution, 660 to 910 ml; and plasma clearance, 18 to 22 ml/min.",Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612530/),min,3.2 to 3.9,9709,DB00009,Alteplase
,3612530,beta T1/2,"After bolus i.v. injection in rabbits with 2.5 kg. b.wt., the disappearance rate of all three forms from plasma could be described by a two-compartment disposition model with the following pharmacokinetic parameters: alpha T1/2, 3.2 to 3.9 min; beta T1/2, 15 to 16 min; volume of the central compartment, 170 to 200 ml; total volume of distribution, 660 to 910 ml; and plasma clearance, 18 to 22 ml/min.",Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612530/),min,15 to 16,9710,DB00009,Alteplase
,3612530,volume of the central compartment,"After bolus i.v. injection in rabbits with 2.5 kg. b.wt., the disappearance rate of all three forms from plasma could be described by a two-compartment disposition model with the following pharmacokinetic parameters: alpha T1/2, 3.2 to 3.9 min; beta T1/2, 15 to 16 min; volume of the central compartment, 170 to 200 ml; total volume of distribution, 660 to 910 ml; and plasma clearance, 18 to 22 ml/min.",Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612530/),ml,170 to 200,9711,DB00009,Alteplase
,3612530,total volume of distribution,"After bolus i.v. injection in rabbits with 2.5 kg. b.wt., the disappearance rate of all three forms from plasma could be described by a two-compartment disposition model with the following pharmacokinetic parameters: alpha T1/2, 3.2 to 3.9 min; beta T1/2, 15 to 16 min; volume of the central compartment, 170 to 200 ml; total volume of distribution, 660 to 910 ml; and plasma clearance, 18 to 22 ml/min.",Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612530/),ml,660 to 910,9712,DB00009,Alteplase
,3612530,plasma clearance,"After bolus i.v. injection in rabbits with 2.5 kg. b.wt., the disappearance rate of all three forms from plasma could be described by a two-compartment disposition model with the following pharmacokinetic parameters: alpha T1/2, 3.2 to 3.9 min; beta T1/2, 15 to 16 min; volume of the central compartment, 170 to 200 ml; total volume of distribution, 660 to 910 ml; and plasma clearance, 18 to 22 ml/min.",Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612530/),[ml] / [min],18 to 22,9713,DB00009,Alteplase
,3612530,T1/2,"Steady-state plasma levels of scu-PA during continuous i.v. infusion were proportional to the dose given, whereas the initial postinfusion disappearance rate of scu-PA from plasma was comparable to that after bolus injection (T1/2 of 5 to 6 min).",Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612530/),min,5 to 6,9714,DB00009,Alteplase
,18444516,half-life,"Streptokinase mainly undergoes renal elimination with a half-life of 11-17 min, while alteplase is eliminating by the liver with a half-life of 4-6 min.",Does impairment of renal and hepatic function influence the metabolism of thrombolytics in patients with myocardial infarction? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18444516/),min,11-17,10493,DB00009,Alteplase
,18444516,half-life,"Streptokinase mainly undergoes renal elimination with a half-life of 11-17 min, while alteplase is eliminating by the liver with a half-life of 4-6 min.",Does impairment of renal and hepatic function influence the metabolism of thrombolytics in patients with myocardial infarction? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18444516/),min,4-6,10494,DB00009,Alteplase
,8772228,half-life,BM 06.022 was injected at a pharmacological dose of 380 micrograms/kg b.w. and it was cleared from the plasma in a biphasic manner with a half-life of about 1 min in the alpha-phase and t1/2 of 20-28 min in the beta-phase.,"Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772228/),min,1,10849,DB00009,Alteplase
,8772228,t1/2,BM 06.022 was injected at a pharmacological dose of 380 micrograms/kg b.w. and it was cleared from the plasma in a biphasic manner with a half-life of about 1 min in the alpha-phase and t1/2 of 20-28 min in the beta-phase.,"Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772228/),min,20-28,10850,DB00009,Alteplase
,8772228,IC50,"BM 06.022 bound with low-affinity to the parenchymal liver cells (550 nM) and the binding of BM 06.022 could be displaced by t-PA (IC50 5.6 nM), indicating that the low-density lipoprotein receptor-related protein (LRP) could be involved in the binding of BM 06.22.","Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8772228/),nM,5.6,10851,DB00009,Alteplase
,2505604,peak rt-PA concentration,"Mean peak rt-PA concentration was 9.8 +/- 3.6 micrograms/ml, total plasma clearance 476 +/- 148 ml/min and dominant half-life 4.8 +/- 1.0 minutes.",Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505604/),[μg] / [ml],9.8,12388,DB00009,Alteplase
,2505604,total plasma clearance,"Mean peak rt-PA concentration was 9.8 +/- 3.6 micrograms/ml, total plasma clearance 476 +/- 148 ml/min and dominant half-life 4.8 +/- 1.0 minutes.",Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505604/),[ml] / [min],476,12389,DB00009,Alteplase
,2505604,dominant half-life,"Mean peak rt-PA concentration was 9.8 +/- 3.6 micrograms/ml, total plasma clearance 476 +/- 148 ml/min and dominant half-life 4.8 +/- 1.0 minutes.",Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505604/),min,4.8,12390,DB00009,Alteplase
,10876808,half life,"However, due to its extremely short half life (approximately 5 min), it is necessary to administer this drug by high-dosage infusion, increasing the possibility of systemic bleeding.","[Research and development of novel modified tissue-type plasminogen activator (t-PA), pamiteplase]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10876808/),min,5,13835,DB00009,Alteplase
,1708425,steady-state plasma t-PA clearance,"In a separate series of experiments, steady-state plasma t-PA clearance increased by 38% (407 +/- 49 vs. 294 +/- 42 ml/min; n = 8, P less than .02) during infusion of iloprost and recovered after its withdrawal.",A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1708425/),[ml] / [min],407,17408,DB00009,Alteplase
,1708425,steady-state plasma t-PA clearance,"In a separate series of experiments, steady-state plasma t-PA clearance increased by 38% (407 +/- 49 vs. 294 +/- 42 ml/min; n = 8, P less than .02) during infusion of iloprost and recovered after its withdrawal.",A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1708425/),[ml] / [min],294,17409,DB00009,Alteplase
,9510983,Vmax/K(m) ratio,"The estimated Vmax/K(m) ratio, the intrinsic metabolic clearance, was 14-19 h-1 using a Michaelis-Menten model.",Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510983/),1/[h],14-19,20336,DB00009,Alteplase
,2207327,t1/2s,"The t1/2s of HT1080 PAI-1 for the initial and beta phases equalled 6.0 and 24.8 minutes, respectively.",The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207327/),min,6.0,22805,DB00009,Alteplase
,2207327,t1/2s,"The t1/2s of HT1080 PAI-1 for the initial and beta phases equalled 6.0 and 24.8 minutes, respectively.",The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207327/),min,24.8,22806,DB00009,Alteplase
,2207327,t1/2s,"The t1/2s of rPAI-1 for the initial and beta phases equalled 8.8 and 34.0 minutes, respectively.",The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207327/),min,8.8,22807,DB00009,Alteplase
,2207327,t1/2s,"The t1/2s of rPAI-1 for the initial and beta phases equalled 8.8 and 34.0 minutes, respectively.",The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207327/),min,34.0,22808,DB00009,Alteplase
,2207327,t1/2,Over 80% of latent rPAI-1 cleared from the circulation within 10 minutes (t1/2 = 1.7 minutes).,The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207327/),min,1.7,22809,DB00009,Alteplase
,8845462,elimination half-lives (T1/2 el),Using the HC II assay the elimination half-lives (T1/2 el) increased from 1.9 h to 3.3 h with increasing doses of LMW-dermatan sulfate.,"Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,1.9,22983,DB00009,Alteplase
,8845462,elimination half-lives (T1/2 el),Using the HC II assay the elimination half-lives (T1/2 el) increased from 1.9 h to 3.3 h with increasing doses of LMW-dermatan sulfate.,"Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,3.3,22984,DB00009,Alteplase
,8845462,T1/2 el,"T1/2 el were 4.3 and 6.9 h with the Heptest assay and 3.3 and 5.1 with the aXa method, respectively.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,4.3,22985,DB00009,Alteplase
,8845462,T1/2 el,"T1/2 el were 4.3 and 6.9 h with the Heptest assay and 3.3 and 5.1 with the aXa method, respectively.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,6.9,22986,DB00009,Alteplase
,8845462,T1/2 el,"T1/2 el were 4.3 and 6.9 h with the Heptest assay and 3.3 and 5.1 with the aXa method, respectively.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),,3.3,22987,DB00009,Alteplase
,8845462,T1/2 el,"T1/2 el were 4.3 and 6.9 h with the Heptest assay and 3.3 and 5.1 with the aXa method, respectively.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),,5.1,22988,DB00009,Alteplase
,8845462,T1/2 el,"T1/2 el was 5.6 h using HC II method, 11.1 h using Heptest and 7.8 h with the aXa activity.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,5.6,22989,DB00009,Alteplase
,8845462,T1/2 el,"T1/2 el was 5.6 h using HC II method, 11.1 h using Heptest and 7.8 h with the aXa activity.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,11.1,22990,DB00009,Alteplase
,8845462,T1/2 el,"T1/2 el was 5.6 h using HC II method, 11.1 h using Heptest and 7.8 h with the aXa activity.","Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845462/),h,7.8,22991,DB00009,Alteplase
,2115513,initial plasma half-life,"The initial plasma half-life following intravenous bolus injection of 0.25 mg/kg in hamsters was 1.2-2.6 min, not significantly different from wild-type rt-PA (2.4 min).",Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115513/),min,1.2-2.6,24216,DB00009,Alteplase
,2115513,initial plasma half-life,"The initial plasma half-life following intravenous bolus injection of 0.25 mg/kg in hamsters was 1.2-2.6 min, not significantly different from wild-type rt-PA (2.4 min).",Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115513/),min,2.4,24217,DB00009,Alteplase
,23411397,half-life,Extensive in vivo PK studies in NOD-SCID mice revealed a half-life of nearly 5h and peak concentration of 5 μM.,"Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411397/),h,5,24607,DB00009,Alteplase
,23411397,peak concentration,Extensive in vivo PK studies in NOD-SCID mice revealed a half-life of nearly 5h and peak concentration of 5 μM.,"Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23411397/),μM,5,24608,DB00009,Alteplase
,20705929,half-life,Pharmacokinetic analysis (n=22) revealed a half-life of approximately 24 hours and linearity of parameters over doses.,Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20705929/),h,24,25184,DB00009,Alteplase
,20705929,half-life,"The half-life of minocycline is approximately 24 hours, allowing every 24-hour dosing.",Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20705929/),h,24,25185,DB00009,Alteplase
,2225359,initial volume of distribution,"The pharmacokinetic parameters for the disposition of rPAI-1 antigen after an intravenous bolus injection of 1.0 or 2.5 mg/kg rPAI-1 were very similar for all three forms: the initial volume of distribution was approximately 60 ml/kg, the initial half-life in plasma was 6 minutes, and the plasma clearance was approximately 4 ml/kg/min.",Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225359/),[ml] / [kg],60,30035,DB00009,Alteplase
,2225359,initial half-life,"The pharmacokinetic parameters for the disposition of rPAI-1 antigen after an intravenous bolus injection of 1.0 or 2.5 mg/kg rPAI-1 were very similar for all three forms: the initial volume of distribution was approximately 60 ml/kg, the initial half-life in plasma was 6 minutes, and the plasma clearance was approximately 4 ml/kg/min.",Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225359/),min,6,30036,DB00009,Alteplase
,2225359,plasma clearance,"The pharmacokinetic parameters for the disposition of rPAI-1 antigen after an intravenous bolus injection of 1.0 or 2.5 mg/kg rPAI-1 were very similar for all three forms: the initial volume of distribution was approximately 60 ml/kg, the initial half-life in plasma was 6 minutes, and the plasma clearance was approximately 4 ml/kg/min.",Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225359/),[ml] / [kg·min],4,30037,DB00009,Alteplase
,2225359,specific activity,"Injection of latent rPAI-1 was associated with a nearly threefold increase in the specific activity of circulating PAI-1 from 2 units/micrograms to 5.0 +/- 1.1 units/micrograms (p less than 0.01) within 1 minute, followed by a cumulative 25-fold increase in specific activity over 1 hour (p = 0.01).",Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225359/),[units] / [μg],2,30038,DB00009,Alteplase
,2225359,specific activity,"Injection of latent rPAI-1 was associated with a nearly threefold increase in the specific activity of circulating PAI-1 from 2 units/micrograms to 5.0 +/- 1.1 units/micrograms (p less than 0.01) within 1 minute, followed by a cumulative 25-fold increase in specific activity over 1 hour (p = 0.01).",Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225359/),[units] / [μg],5.0,30039,DB00009,Alteplase
,8097691,total plasma clearance (CL),"Intravenous administration of 200 kU/kg of BM 06.022 or alteplase over 15 sec to rats with hepatic failure or olive oil pretreatment as control did not significantly alter the total plasma clearance (CL) of BM 06.022 vs. control (4.9 +/- 0.5 vs. 5.7 +/- 0.5 ml.min-1 x kg-1, NS) in contrast to alteplase (32.1 +/- 6.5 vs. 82.3 +/- 12.9 ml.min-1 x kg-1, p < 0.05).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],4.9,30181,DB00009,Alteplase
,8097691,total plasma clearance (CL),"Intravenous administration of 200 kU/kg of BM 06.022 or alteplase over 15 sec to rats with hepatic failure or olive oil pretreatment as control did not significantly alter the total plasma clearance (CL) of BM 06.022 vs. control (4.9 +/- 0.5 vs. 5.7 +/- 0.5 ml.min-1 x kg-1, NS) in contrast to alteplase (32.1 +/- 6.5 vs. 82.3 +/- 12.9 ml.min-1 x kg-1, p < 0.05).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],5.7,30182,DB00009,Alteplase
,8097691,total plasma clearance (CL),"Intravenous administration of 200 kU/kg of BM 06.022 or alteplase over 15 sec to rats with hepatic failure or olive oil pretreatment as control did not significantly alter the total plasma clearance (CL) of BM 06.022 vs. control (4.9 +/- 0.5 vs. 5.7 +/- 0.5 ml.min-1 x kg-1, NS) in contrast to alteplase (32.1 +/- 6.5 vs. 82.3 +/- 12.9 ml.min-1 x kg-1, p < 0.05).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],32.1,30183,DB00009,Alteplase
,8097691,total plasma clearance (CL),"Intravenous administration of 200 kU/kg of BM 06.022 or alteplase over 15 sec to rats with hepatic failure or olive oil pretreatment as control did not significantly alter the total plasma clearance (CL) of BM 06.022 vs. control (4.9 +/- 0.5 vs. 5.7 +/- 0.5 ml.min-1 x kg-1, NS) in contrast to alteplase (32.1 +/- 6.5 vs. 82.3 +/- 12.9 ml.min-1 x kg-1, p < 0.05).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],82.3,30184,DB00009,Alteplase
,8097691,CL,"Renal insufficiency increased the CL of BM 06.022 vs. sham surgery (3.1 +/- 0.4 vs. 6.3 +/- 0.5 ml.min-1 x kg-1, p < 0.05) in contrast to alteplase (33.2 +/- 5.2 vs. 37.2 +/- 7.2 ml.min-1 x kg-1, NS).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],3.1,30185,DB00009,Alteplase
,8097691,CL,"Renal insufficiency increased the CL of BM 06.022 vs. sham surgery (3.1 +/- 0.4 vs. 6.3 +/- 0.5 ml.min-1 x kg-1, p < 0.05) in contrast to alteplase (33.2 +/- 5.2 vs. 37.2 +/- 7.2 ml.min-1 x kg-1, NS).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],6.3,30186,DB00009,Alteplase
,8097691,CL,"Renal insufficiency increased the CL of BM 06.022 vs. sham surgery (3.1 +/- 0.4 vs. 6.3 +/- 0.5 ml.min-1 x kg-1, p < 0.05) in contrast to alteplase (33.2 +/- 5.2 vs. 37.2 +/- 7.2 ml.min-1 x kg-1, NS).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],33.2,30187,DB00009,Alteplase
,8097691,CL,"Renal insufficiency increased the CL of BM 06.022 vs. sham surgery (3.1 +/- 0.4 vs. 6.3 +/- 0.5 ml.min-1 x kg-1, p < 0.05) in contrast to alteplase (33.2 +/- 5.2 vs. 37.2 +/- 7.2 ml.min-1 x kg-1, NS).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],37.2,30188,DB00009,Alteplase
,8097691,half-life,In vitro incubation of 2000 U/ml BM 06.022 or alteplase in citrate blood and plasma demonstrated a decrease of the plasma concentration with a shorter (p < 0.001) half-life for BM 06.022 than for alteplase in blood (71.9 +/- 3.1 vs. 130 +/- 3.3 min) and in plasma (62.9 +/- 1.2 vs. 129.9 +/- 5.3 min).,Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),min,71.9,30189,DB00009,Alteplase
,8097691,half-life,In vitro incubation of 2000 U/ml BM 06.022 or alteplase in citrate blood and plasma demonstrated a decrease of the plasma concentration with a shorter (p < 0.001) half-life for BM 06.022 than for alteplase in blood (71.9 +/- 3.1 vs. 130 +/- 3.3 min) and in plasma (62.9 +/- 1.2 vs. 129.9 +/- 5.3 min).,Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),min,130,30190,DB00009,Alteplase
,8097691,half-life,In vitro incubation of 2000 U/ml BM 06.022 or alteplase in citrate blood and plasma demonstrated a decrease of the plasma concentration with a shorter (p < 0.001) half-life for BM 06.022 than for alteplase in blood (71.9 +/- 3.1 vs. 130 +/- 3.3 min) and in plasma (62.9 +/- 1.2 vs. 129.9 +/- 5.3 min).,Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),min,62.9,30191,DB00009,Alteplase
,8097691,half-life,In vitro incubation of 2000 U/ml BM 06.022 or alteplase in citrate blood and plasma demonstrated a decrease of the plasma concentration with a shorter (p < 0.001) half-life for BM 06.022 than for alteplase in blood (71.9 +/- 3.1 vs. 130 +/- 3.3 min) and in plasma (62.9 +/- 1.2 vs. 129.9 +/- 5.3 min).,Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),min,129.9,30192,DB00009,Alteplase
,7635954,plasma half-life,Expression of the 39-kD protein resulted in a sustained plasma concentration and an increase in the plasma half-life of 125I-t-PA from less than 1 min to 4-5 min.,Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7635954/),min,less,30193,DB00009,Alteplase
,7635954,plasma half-life,Expression of the 39-kD protein resulted in a sustained plasma concentration and an increase in the plasma half-life of 125I-t-PA from less than 1 min to 4-5 min.,Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7635954/),min,1,30194,DB00009,Alteplase
,7635954,plasma half-life,Expression of the 39-kD protein resulted in a sustained plasma concentration and an increase in the plasma half-life of 125I-t-PA from less than 1 min to 4-5 min.,Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7635954/),min,4-5,30195,DB00009,Alteplase
,7635954,plasma half-life,Blockade of the mannose receptor by intravenous administration of ovalbumin also prolonged the plasma half-life of 125I-t-PA to 3-4 min.,Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7635954/),min,3-4,30196,DB00009,Alteplase
>,7635954,plasma half-life,"Furthermore, a dramatic increase of the plasma half-life of 125I-t-PA (>> 20 min) was observed in mice overexpressing 39-kD protein and administered ovalbumin +/- fucosyl-BSA.",Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7635954/),min,20,30197,DB00009,Alteplase
,3141199,plasma half-life,There was no effect of the route on the plasma half-life of DDAVP which ranged from 2.7 to 4.6 h.,Pharmacokinetics and haematological effects of desmopressin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141199/),h,2.7 to 4.6,30448,DB00009,Alteplase
,3141199,bioavailability,"Based on AUC data, bioavailability via the two s.c. methods and the i.n. route was 112%, 94% and 2%, respectively.",Pharmacokinetics and haematological effects of desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141199/),%,112,30449,DB00009,Alteplase
,3141199,bioavailability,"Based on AUC data, bioavailability via the two s.c. methods and the i.n. route was 112%, 94% and 2%, respectively.",Pharmacokinetics and haematological effects of desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141199/),%,94,30450,DB00009,Alteplase
,3141199,bioavailability,"Based on AUC data, bioavailability via the two s.c. methods and the i.n. route was 112%, 94% and 2%, respectively.",Pharmacokinetics and haematological effects of desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141199/),%,2,30451,DB00009,Alteplase
,8656642,plasma clearance,TP-9201 had a plasma clearance of 9.9 +/- 2 ml/min/kg and a volume of distribution that was larger than plasma volume.,"Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8656642/),[ml] / [kg·min],9.9,31019,DB00009,Alteplase
,8656642,half life (t1/2),"After discontinuation of TP-9201, recovery of platelet aggregation had a half life (t1/2) of 2-3 h and was complete < or = 24 h.","Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8656642/),h,2-3,31020,DB00009,Alteplase
,12074692,distribution plasma half-life,The distribution plasma half-life of approximately 35 min for lanoteplase was at least five times longer than that of alteplase.,Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12074692/),min,35,36764,DB00009,Alteplase
,12074692,plasma clearance,"Lanoteplase plasma clearance averaged 3 L/h (50 ml/min), whereas the mean plasma clearance of approximately 24 L/h (400 ml/min) for alteplase approaches hepatic blood flow following acute myocardial infarction.",Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12074692/),[l] / [h],3,36765,DB00009,Alteplase
,12074692,plasma clearance,"Lanoteplase plasma clearance averaged 3 L/h (50 ml/min), whereas the mean plasma clearance of approximately 24 L/h (400 ml/min) for alteplase approaches hepatic blood flow following acute myocardial infarction.",Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12074692/),[l] / [h],24,36766,DB00009,Alteplase
,10438721,clearance rate,17alpha-Ethinyl estradiol (EE) treatment resulted in a significant increase in the clearance rate of recombinant human t-PA in mice (0.46 mL/min in treated mice v 0. 32 mL/min in controls; P <.01).,Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.46,44028,DB00009,Alteplase
,10438721,clearance rate,17alpha-Ethinyl estradiol (EE) treatment resulted in a significant increase in the clearance rate of recombinant human t-PA in mice (0.46 mL/min in treated mice v 0. 32 mL/min in controls; P <.01).,Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0. 32,44029,DB00009,Alteplase
,10438721,area under the curve [AUC],"The clearance of endogenous, bradykinin-released t-PA in rats was also significantly increased after EE treatment (area under the curve [AUC], 24.9 ng/mL. min in treated animals v 31.9 ng/mL. min in controls; P <.05).",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ng] / [min·ml],24.9,44030,DB00009,Alteplase
,10438721,area under the curve [AUC],"The clearance of endogenous, bradykinin-released t-PA in rats was also significantly increased after EE treatment (area under the curve [AUC], 24.9 ng/mL. min in treated animals v 31.9 ng/mL. min in controls; P <.05).",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ng] / [min·ml],31.9,44031,DB00009,Alteplase
,10438721,clearance,"Inhibition of LRP by intravenous injection of receptor-associated protein (RAP) as a recombinant fusion protein with Salmonella japonicum glutathione S-transferase (GST) significantly retarded t-PA clearance in control mice (from 0.41 to 0.25 mL/min; n = 5, P <.001) and EE-treated mice (from 0.66 to 0.35 mL/min; n = 5, P <.005), but did not eliminate the difference in clearance capacity between the 2 experimental groups.",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.41 to 0.25,44032,DB00009,Alteplase
,10438721,clearance,"Inhibition of LRP by intravenous injection of receptor-associated protein (RAP) as a recombinant fusion protein with Salmonella japonicum glutathione S-transferase (GST) significantly retarded t-PA clearance in control mice (from 0.41 to 0.25 mL/min; n = 5, P <.001) and EE-treated mice (from 0.66 to 0.35 mL/min; n = 5, P <.005), but did not eliminate the difference in clearance capacity between the 2 experimental groups.",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.66 to 0.35,44033,DB00009,Alteplase
,10438721,clearances,"In contrast, administration of mannan, a mannose receptor antagonist, resulted in identical clearances (0.22 mL/min in controls and 0.24 mL/min in EE-treated mice).",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.22,44034,DB00009,Alteplase
,10438721,clearances,"In contrast, administration of mannan, a mannose receptor antagonist, resulted in identical clearances (0.22 mL/min in controls and 0.24 mL/min in EE-treated mice).",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.24,44035,DB00009,Alteplase
,3931294,half-life,The half-life of fibrinolytically active tPA in hepatectomized rabbits was 40 minutes compared to 2 minutes in intact rabbits.,Turnover of tissue plasminogen activator in normal and hepatectomized rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3931294/),min,40,45460,DB00009,Alteplase
,3931294,half-life,The half-life of fibrinolytically active tPA in hepatectomized rabbits was 40 minutes compared to 2 minutes in intact rabbits.,Turnover of tissue plasminogen activator in normal and hepatectomized rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3931294/),min,2,45461,DB00009,Alteplase
,1407000,half-life,BM 06.021 demonstrated a longer (p less than 0.05) half-life (5.6 +/- 2.6 vs. 2.1 +/- 0.3 min) and a lower (p less than 0.05) clearance rate (7.5 +/- 0.8 vs. 22.2 +/- 3.1 ml.min-1.kg-1) than alteplase in rabbits upon intravenous infusion.,Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1407000/),min,5.6,50245,DB00009,Alteplase
,1407000,half-life,BM 06.021 demonstrated a longer (p less than 0.05) half-life (5.6 +/- 2.6 vs. 2.1 +/- 0.3 min) and a lower (p less than 0.05) clearance rate (7.5 +/- 0.8 vs. 22.2 +/- 3.1 ml.min-1.kg-1) than alteplase in rabbits upon intravenous infusion.,Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1407000/),min,2.1,50246,DB00009,Alteplase
,1407000,clearance rate,BM 06.021 demonstrated a longer (p less than 0.05) half-life (5.6 +/- 2.6 vs. 2.1 +/- 0.3 min) and a lower (p less than 0.05) clearance rate (7.5 +/- 0.8 vs. 22.2 +/- 3.1 ml.min-1.kg-1) than alteplase in rabbits upon intravenous infusion.,Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1407000/),[ml] / [kg·min],7.5,50247,DB00009,Alteplase
,1407000,clearance rate,BM 06.021 demonstrated a longer (p less than 0.05) half-life (5.6 +/- 2.6 vs. 2.1 +/- 0.3 min) and a lower (p less than 0.05) clearance rate (7.5 +/- 0.8 vs. 22.2 +/- 3.1 ml.min-1.kg-1) than alteplase in rabbits upon intravenous infusion.,Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1407000/),[ml] / [kg·min],22.2,50248,DB00009,Alteplase
,1407000,effective dose of 50% thrombolysis (ED50),The dose-response curve of BM 06.021 for thrombolysis in a rabbit model of jugular vein thrombosis was located to the left of that for alteplase with a 2.1-fold lower effective dose of 50% thrombolysis (ED50) of BM 06.021 (207 vs. 436 kU/kg).,Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1407000/),[ku] / [kg],207,50249,DB00009,Alteplase
,1407000,effective dose of 50% thrombolysis (ED50),The dose-response curve of BM 06.021 for thrombolysis in a rabbit model of jugular vein thrombosis was located to the left of that for alteplase with a 2.1-fold lower effective dose of 50% thrombolysis (ED50) of BM 06.021 (207 vs. 436 kU/kg).,Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1407000/),[ku] / [kg],436,50250,DB00009,Alteplase
,1407000,residual thrombus,The residual thrombus wet weight did not significantly differ between BM 06.021 and alteplase (5.7 +/- 1.8 vs. 6.3 +/- 1.1 mg).,Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1407000/),mg,5.7,50251,DB00009,Alteplase
,1407000,wet weight,The residual thrombus wet weight did not significantly differ between BM 06.021 and alteplase (5.7 +/- 1.8 vs. 6.3 +/- 1.1 mg).,Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1407000/),mg,5.7,50252,DB00009,Alteplase
,1407000,wet weight,The residual thrombus wet weight did not significantly differ between BM 06.021 and alteplase (5.7 +/- 1.8 vs. 6.3 +/- 1.1 mg).,Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1407000/),mg,6.3,50253,DB00009,Alteplase
,8269200,initial half-life,K1K2Pu disappeared from the plasma with an initial half-life of 9 min and a clearance of approximately 50 ml/min.,"Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269200/),min,9,51617,DB00009,Alteplase
,8269200,clearance,K1K2Pu disappeared from the plasma with an initial half-life of 9 min and a clearance of approximately 50 ml/min.,"Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269200/),[ml] / [min],50,51618,DB00009,Alteplase
,32811752,peak,The D-dimer level trended up and reached a peak median level of 1.35 mg/L of fibrinogen equivalence units (FEU) at 15 minutes after protamine administration.,A Pharmacokinetic and Pharmacodynamic Investigation of an ε-Aminocaproic Acid Regimen Designed for Cardiac Surgery With Cardiopulmonary Bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32811752/),[mg] / [l],1.35,54875,DB00009,Alteplase
,32811752,chest tube output,"The median 24-hour chest tube output was 445 (180-1,011) mL.",A Pharmacokinetic and Pharmacodynamic Investigation of an ε-Aminocaproic Acid Regimen Designed for Cardiac Surgery With Cardiopulmonary Bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32811752/),ml,445,54876,DB00009,Alteplase
,2496774,half-life (T1/2),"Because of its rapid half-life (T1/2) of approximately five minutes, intravenous (IV) infusion of large doses (approximately 100 mg) are required in patients treated for myocardial infarction.",Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496774/),min,five,57634,DB00009,Alteplase
,2496774,alpha-phase T1/2,"Both glycosylated and nonglycosylated wild-type t-PA cleared in an exponential biphasic manner, with an initial alpha-phase T1/2 of 0.8 and 1.9 minutes, respectively.",Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496774/),min,0.8,57635,DB00009,Alteplase
,2496774,alpha-phase T1/2,"Both glycosylated and nonglycosylated wild-type t-PA cleared in an exponential biphasic manner, with an initial alpha-phase T1/2 of 0.8 and 1.9 minutes, respectively.",Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496774/),min,1.9,57636,DB00009,Alteplase
,2496774,T1/2,"All other proteins tested, except for delta E t-PA, demonstrated primarily monophasic clearance patterns with T1/2 ranging between 12 and 27 minutes, and reduced uptake in the liver.",Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496774/),min,12 and 27,57637,DB00009,Alteplase
,2496774,alpha-phase T1/2,"delta E t-PA however, cleared in a biphasic manner with an alpha-phase T1/2 of 2.1 minutes.",Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496774/),min,2.1,57638,DB00009,Alteplase
,1554639,mean clearance time,Collagen shield tPA delivery shortened the time to fibrin clot lysis by 50% (mean clearance time = 49 +/- 23 hours; P less than .05).,Collagen shield delivery of tissue plasminogen activator: functional and pharmacokinetic studies of anterior segment delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554639/),h,49,58248,DB00009,Alteplase
,1909151,plasma tissue plasminogen activator (t-PA),Mean (SD) plasma tissue plasminogen activator (t-PA) concentration reached 4434.8 (2117.8) and 4233.3 (2217.5) ng/ml within 10 minutes of each bolus and fell to 425.8 (288.3) ng/ml between boluses.,A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909151/),[ng] / [ml],4434.8,61824,DB00009,Alteplase
,1909151,plasma tissue plasminogen activator (t-PA),Mean (SD) plasma tissue plasminogen activator (t-PA) concentration reached 4434.8 (2117.8) and 4233.3 (2217.5) ng/ml within 10 minutes of each bolus and fell to 425.8 (288.3) ng/ml between boluses.,A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909151/),[ng] / [ml],4233.3,61825,DB00009,Alteplase
,1909151,plasma tissue plasminogen activator (t-PA),Mean (SD) plasma tissue plasminogen activator (t-PA) concentration reached 4434.8 (2117.8) and 4233.3 (2217.5) ng/ml within 10 minutes of each bolus and fell to 425.8 (288.3) ng/ml between boluses.,A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909151/),[ng] / [ml],425.8,61826,DB00009,Alteplase
,1909151,concentration,Mean (SD) plasma tissue plasminogen activator (t-PA) concentration reached 4434.8 (2117.8) and 4233.3 (2217.5) ng/ml within 10 minutes of each bolus and fell to 425.8 (288.3) ng/ml between boluses.,A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909151/),[ng] / [ml],4434.8,61827,DB00009,Alteplase
,1909151,concentration,Mean (SD) plasma tissue plasminogen activator (t-PA) concentration reached 4434.8 (2117.8) and 4233.3 (2217.5) ng/ml within 10 minutes of each bolus and fell to 425.8 (288.3) ng/ml between boluses.,A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909151/),[ng] / [ml],4233.3,61828,DB00009,Alteplase
,1909151,concentration,Mean (SD) plasma tissue plasminogen activator (t-PA) concentration reached 4434.8 (2117.8) and 4233.3 (2217.5) ng/ml within 10 minutes of each bolus and fell to 425.8 (288.3) ng/ml between boluses.,A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909151/),[ng] / [ml],425.8,61829,DB00009,Alteplase
,1909151,peak concentrations,"The estimated peak concentrations at two minutes after boluses were 12,389 (8580) ng/ml and 10,811 (6802) ng/ml.",A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909151/),[ng] / [ml],"12,389",61830,DB00009,Alteplase
,1909151,peak concentrations,"The estimated peak concentrations at two minutes after boluses were 12,389 (8580) ng/ml and 10,811 (6802) ng/ml.",A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909151/),[ng] / [ml],"10,811",61831,DB00009,Alteplase
,1909151,volume of distribution,"The derived pharmacokinetic variables were volume of distribution 3.11 (1.89) 1, clearance 21.3 (9.3) 1/h, half life 5.9 (1.7) minutes.",A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909151/),1,3.11,61832,DB00009,Alteplase
,1909151,clearance,"The derived pharmacokinetic variables were volume of distribution 3.11 (1.89) 1, clearance 21.3 (9.3) 1/h, half life 5.9 (1.7) minutes.",A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909151/),[1] / [h],21.3,61833,DB00009,Alteplase
,1909151,half life,"The derived pharmacokinetic variables were volume of distribution 3.11 (1.89) 1, clearance 21.3 (9.3) 1/h, half life 5.9 (1.7) minutes.",A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909151/),min,5.9,61834,DB00009,Alteplase
,8907616,half-life,The 39-kDa protein is synthesized by both cell types and has an average half-life of 15 hours.,The 39-kDa protein regulates LRP activity in cultured endothelial and smooth muscle cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907616/),h,15,62270,DB00009,Alteplase
,3142086,apparent Mr,"Using a combination of chromatography on Sephadex G25, Sephadex G75 and Heparin Sepharose CL6B we have isolated two fibrinolytically active species, which, under non-reduced SDS PAGE, have apparent Mr = 38,000 and 56,000.","Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142086/),,"38,000",62635,DB00009,Alteplase
,3142086,apparent Mr,"Using a combination of chromatography on Sephadex G25, Sephadex G75 and Heparin Sepharose CL6B we have isolated two fibrinolytically active species, which, under non-reduced SDS PAGE, have apparent Mr = 38,000 and 56,000.","Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3142086/),,"56,000",62636,DB00009,Alteplase
,1909220,maximal rate,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,720,64541,DB00009,Alteplase
,1909220,maximal rate,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,45,64542,DB00009,Alteplase
,1909220,maximal rate,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,210,64543,DB00009,Alteplase
,1909220,maximal rate,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,49,64544,DB00009,Alteplase
,1909220,maximal rate,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,310,64545,DB00009,Alteplase
,1909220,l,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,49,64546,DB00009,Alteplase
,1909220,l,"In hamsters with pulmonary embolism, in rabbits with jugular vein thrombosis, and in baboons with femoral vein thrombosis, the thrombolytic potency (percent lysis per milligram of compound administered per kilogram of body weight) of t-PA-delta FE/scu-PA-e was significantly higher than that of recombinant scu-PA (rscu-PA, Saruplase) as shown by a maximal rate of 720 +/- 170% versus 45 +/- 5% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in hamsters, 210 +/- 18% versus 49 +/- 3% lysis per milligram of compound per kilogram of body weight (mean +/- SEM, p less than 0.01) in rabbits, and 310 +/- 73% versus 90 +/- 0.3% lysis per milligram of compound per kilogram of body weight (p less than 0.01) in baboons.",Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909220/),%,90,64547,DB00009,Alteplase
,1909815,systemic clearance,"The systemic clearance ranged from 2.5 to 3.0 ml.min-1.kg-1 and did not show dose-dependency, in contrast to alteplase which was studied at doses of 200, 400, 800, and 1600 kU/kg.",Pharmacokinetic properties of an Escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909815/),[ml] / [kg·min],2.5 to 3.0,66036,DB00009,Alteplase
,1909815,dominant half-life,"The dose-groups of BM 06.022 showed an average dominant half-life ranging from 11.6 to 15.4 min, which was about five-times longer than the dominant half-life values of alteplase (2.3 to 4.5 min).",Pharmacokinetic properties of an Escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909815/),min,11.6 to 15.4,66037,DB00009,Alteplase
,1909815,dominant half-life,"The dose-groups of BM 06.022 showed an average dominant half-life ranging from 11.6 to 15.4 min, which was about five-times longer than the dominant half-life values of alteplase (2.3 to 4.5 min).",Pharmacokinetic properties of an Escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1909815/),min,2.3 to 4.5,66038,DB00009,Alteplase
,25739904,concentrations,"Median CSF TPA concentrations in seven TPA-treated patients were 525 (IQR 352-2129), 323 (233-413), and 47 (29-283) ng/ml, respectively, at 1, 6, and 12 h after drug administration.",Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25739904/),[ng] / [ml],525,69372,DB00009,Alteplase
,25739904,concentrations,"Median CSF TPA concentrations in seven TPA-treated patients were 525 (IQR 352-2129), 323 (233-413), and 47 (29-283) ng/ml, respectively, at 1, 6, and 12 h after drug administration.",Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25739904/),[ng] / [ml],323,69373,DB00009,Alteplase
,25739904,concentrations,"Median CSF TPA concentrations in seven TPA-treated patients were 525 (IQR 352-2129), 323 (233-413), and 47 (29-283) ng/ml, respectively, at 1, 6, and 12 h after drug administration.",Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25739904/),[ng] / [ml],47,69374,DB00009,Alteplase
,25739904,Peak concentrations,Peak concentrations varied markedly (401-8398 ng/ml).,Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25739904/),[ng] / [ml],401-8398,69375,DB00009,Alteplase
,1908140,effective dose of 50% thrombolysis (ED50),The effective dose of 50% thrombolysis (ED50) obtained by half-logarithmic regression analysis was 163 kU/kg (= 0.28 mg/kg) for BM 06.022 and 871 kU/kg (= 1.09 mg/kg) for alteplase.,Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),[ku] / [kg],163,79342,DB00009,Alteplase
,1908140,effective dose of 50% thrombolysis (ED50),The effective dose of 50% thrombolysis (ED50) obtained by half-logarithmic regression analysis was 163 kU/kg (= 0.28 mg/kg) for BM 06.022 and 871 kU/kg (= 1.09 mg/kg) for alteplase.,Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),[ku] / [kg],871,79343,DB00009,Alteplase
,1908140,half-life,"Pharmacokinetic analysis for plasma activity at a dose of 400 kU/kg revealed a half-life of 18.9 +/- 1.5 min for BM 06.022, whereas alteplase was distributed with a half-life of 2.1 +/- 0.1 min, accounting for 86.7 +/- 1.9% of the total AUC, followed by a beta-phase with a half-life of 13.8 +/- 0.9 min.",Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),min,18.9,79344,DB00009,Alteplase
,1908140,half-life,"Pharmacokinetic analysis for plasma activity at a dose of 400 kU/kg revealed a half-life of 18.9 +/- 1.5 min for BM 06.022, whereas alteplase was distributed with a half-life of 2.1 +/- 0.1 min, accounting for 86.7 +/- 1.9% of the total AUC, followed by a beta-phase with a half-life of 13.8 +/- 0.9 min.",Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),min,2.1,79345,DB00009,Alteplase
,1908140,half-life,"Pharmacokinetic analysis for plasma activity at a dose of 400 kU/kg revealed a half-life of 18.9 +/- 1.5 min for BM 06.022, whereas alteplase was distributed with a half-life of 2.1 +/- 0.1 min, accounting for 86.7 +/- 1.9% of the total AUC, followed by a beta-phase with a half-life of 13.8 +/- 0.9 min.",Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),min,13.8,79346,DB00009,Alteplase
,1908140,Plasma clearance,Plasma clearance of BM 06.022 was 4.7 +/- 0.7 ml min-1 kg-1 compared with 20 +/- 1.2 ml min-1 kg-1 for alteplase.,Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),[ml] / [kg·min],4.7,79347,DB00009,Alteplase
,1908140,Plasma clearance,Plasma clearance of BM 06.022 was 4.7 +/- 0.7 ml min-1 kg-1 compared with 20 +/- 1.2 ml min-1 kg-1 for alteplase.,Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908140/),[ml] / [kg·min],20,79348,DB00009,Alteplase
,2515604,initial half-life (t 1/2 alpha),"The initial half-life (t 1/2 alpha) was the same, about 1.5 minutes, for both compounds, irrespective of method of analysis.",Elimination of native and carbohydrate-modified tissue plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515604/),min,1.5,83836,DB00009,Alteplase
,2515604,late half-life (t 1/2 beta),"The late half-life (t 1/2 beta) was also the same, about 15 minutes, for both compounds.",Elimination of native and carbohydrate-modified tissue plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515604/),min,15,83837,DB00009,Alteplase
,3099771,half-lives,The vast majority of t-PA and the heavy chain disappeared from the blood circulation with half-lives of 2.3 and 1.0 min respectively.,Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099771/),min,2.3,83940,DB00009,Alteplase
,3099771,half-lives,The vast majority of t-PA and the heavy chain disappeared from the blood circulation with half-lives of 2.3 and 1.0 min respectively.,Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099771/),min,1.0,83941,DB00009,Alteplase
,3099771,half-life,"The disappearance of di-isopropylphospho-light chain, which has a blocked active site, was nearly monophasic, with a half-life of 5.7 min.",Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099771/),min,5.7,83942,DB00009,Alteplase
,1371932,reperfusion times,"The median reperfusion times in the bat-PA and t-PA groups were 24 and greater than or equal to 131 minutes, respectively.",Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1371932/),min,24,85096,DB00009,Alteplase
greater,1371932,reperfusion times,"The median reperfusion times in the bat-PA and t-PA groups were 24 and greater than or equal to 131 minutes, respectively.",Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1371932/),min,131,85097,DB00009,Alteplase
,1371932,reperfusion times,"The mean reperfusion times (+/- SEM) in the recanalized bat-PA- and t-PA-treated dogs were similar (20 +/- 5 and 11 +/- 2 minutes, respectively, p = NS).",Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1371932/),min,20,85098,DB00009,Alteplase
,1371932,reperfusion times,"The mean reperfusion times (+/- SEM) in the recanalized bat-PA- and t-PA-treated dogs were similar (20 +/- 5 and 11 +/- 2 minutes, respectively, p = NS).",Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1371932/),min,11,85099,DB00009,Alteplase
,1371932,Maxim,"Maximal blood flow after reperfusion was greater with bat-PA than with t-PA (80 +/- 10% and 41 +/- 15% of control flow, respectively, p less than 0.05).",Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1371932/),,80,85100,DB00009,Alteplase
,1371932,reocclusion time,"Furthermore, the median reocclusion time was markedly delayed in the bat-PA group relative to the t-PA group (131 versus 34 minutes, respectively, p less than 0.05).",Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1371932/),min,131,85101,DB00009,Alteplase
,1371932,reocclusion time,"Furthermore, the median reocclusion time was markedly delayed in the bat-PA group relative to the t-PA group (131 versus 34 minutes, respectively, p less than 0.05).",Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1371932/),min,34,85102,DB00009,Alteplase
,1371932,half-life (t1/2),"The clearance profile for t-PA was monoexponential, with a half-life (t1/2) of 2.4 +/- 0.3 minutes and a mean residence time of 3.5 +/- 0.4 minutes.",Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1371932/),min,2.4,85103,DB00009,Alteplase
,1371932,mean residence time,"The clearance profile for t-PA was monoexponential, with a half-life (t1/2) of 2.4 +/- 0.3 minutes and a mean residence time of 3.5 +/- 0.4 minutes.",Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1371932/),min,3.5,85104,DB00009,Alteplase
,1371932,t1/2 alpha,"The clearance profile for bat-PA was biexponential, with a t1/2 alpha of 0.9 +/- 0.2 minutes, a t1/2 beta of 20.2 +/- 2.7 minutes, and a mean residence time of 21.3 +/- 4.3 minutes.",Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1371932/),min,0.9,85105,DB00009,Alteplase
,1371932,t1/2 beta,"The clearance profile for bat-PA was biexponential, with a t1/2 alpha of 0.9 +/- 0.2 minutes, a t1/2 beta of 20.2 +/- 2.7 minutes, and a mean residence time of 21.3 +/- 4.3 minutes.",Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1371932/),min,20.2,85106,DB00009,Alteplase
,1371932,mean residence time,"The clearance profile for bat-PA was biexponential, with a t1/2 alpha of 0.9 +/- 0.2 minutes, a t1/2 beta of 20.2 +/- 2.7 minutes, and a mean residence time of 21.3 +/- 4.3 minutes.",Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1371932/),min,21.3,85107,DB00009,Alteplase
,10806604,initial half-life,Tenecteplase exhibited biphasic elimination from the plasma with a mean initial half-life of 22 minutes and a mean terminal half-life of 115 minutes.,Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806604/),min,22,107111,DB00009,Alteplase
,10806604,terminal half-life,Tenecteplase exhibited biphasic elimination from the plasma with a mean initial half-life of 22 minutes and a mean terminal half-life of 115 minutes.,Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806604/),min,115,107112,DB00009,Alteplase
,10806604,plasma clearance,The mean plasma clearance was 105 mL/min and did not depend on tenecteplase dose over the dose range studied.,Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806604/),[ml] / [min],105,107113,DB00009,Alteplase
,7740462,half-life,Activity assays on serial samples showed a dose-dependent decline of BM 06.022 activity with a half-life from 72 min at 0.3 microgram/ml to 38 min at 10 micrograms/ml.,"In vitro stability of a tissue-type plasminogen activator mutant, BM 06.022, in human plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740462/),min,72,108548,DB00009,Alteplase
,7740462,half-life,Activity assays on serial samples showed a dose-dependent decline of BM 06.022 activity with a half-life from 72 min at 0.3 microgram/ml to 38 min at 10 micrograms/ml.,"In vitro stability of a tissue-type plasminogen activator mutant, BM 06.022, in human plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740462/),min,38,108549,DB00009,Alteplase
,12492611,total,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],62.9,108641,DB00009,Alteplase
,12492611,total,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],8.3,108642,DB00009,Alteplase
,12492611,total,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],237.2,108643,DB00009,Alteplase
,12492611,free,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],62.9,108644,DB00009,Alteplase
,12492611,free,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],8.3,108645,DB00009,Alteplase
,12492611,free,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],237.2,108646,DB00009,Alteplase
,12492611,free,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],111.0,108647,DB00009,Alteplase
,12492611,TFPI,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],8.3,108648,DB00009,Alteplase
,12492611,TFPI,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],237.2,108649,DB00009,Alteplase
,12492611,TFPI,Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],111.0,108650,DB00009,Alteplase
,12492611,release rate,The TFPI release rate rapidly increased to maximum of 200 +/- 45 micro g min-1 after 17.5 min heparin infusion but did not increase further although heparin concentrations further doubled.,Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[μg] / [min],200,108651,DB00009,Alteplase
,12492611,antigen,"In contrast to TFPI, t-PA antigen decreased from 5.6 +/- 1.0 at baseline to 4.5 +/- 1.0 ng ml-1 at the end of infusion (t = 40 min) (difference of 1.1 ng ml-1 (95% confidence interval; 0.9, 1.3).",Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],5.6,108652,DB00009,Alteplase
,12492611,antigen,"In contrast to TFPI, t-PA antigen decreased from 5.6 +/- 1.0 at baseline to 4.5 +/- 1.0 ng ml-1 at the end of infusion (t = 40 min) (difference of 1.1 ng ml-1 (95% confidence interval; 0.9, 1.3).",Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492611/),[ng] / [ml],4.5,108653,DB00009,Alteplase
,3095944,maximum plasma concentrations,Mean maximum plasma concentrations were 1080 and 1560 ng/ml respectively.,Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095944/),[ng] / [ml],1080,108781,DB00009,Alteplase
,3095944,maximum plasma concentrations,Mean maximum plasma concentrations were 1080 and 1560 ng/ml respectively.,Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095944/),[ng] / [ml],1560,108782,DB00009,Alteplase
,3095944,steady state level,The steady state level during subsequent maintenance infusion of 30 mg over 6 h was 250 ng/ml.,Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095944/),[ng] / [ml],250,108783,DB00009,Alteplase
,3095944,t1/2 alpha,"The pharmacokinetics of rt-PA showed a bi-exponential disappearance from plasma consistent with a 2-compartment model of t1/2 alpha = 5.7 min, a t1/2 beta = 1.3 h and a total clearance of 380 ml/min.",Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095944/),min,5.7,108784,DB00009,Alteplase
,3095944,t1/2 beta,"The pharmacokinetics of rt-PA showed a bi-exponential disappearance from plasma consistent with a 2-compartment model of t1/2 alpha = 5.7 min, a t1/2 beta = 1.3 h and a total clearance of 380 ml/min.",Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095944/),h,1.3,108785,DB00009,Alteplase
,3095944,total clearance,"The pharmacokinetics of rt-PA showed a bi-exponential disappearance from plasma consistent with a 2-compartment model of t1/2 alpha = 5.7 min, a t1/2 beta = 1.3 h and a total clearance of 380 ml/min.",Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3095944/),[ml] / [min],380,108786,DB00009,Alteplase
,12452736,plasma half-life,"Specific mutations at three sites in the alteplase molecule result in 15-fold higher fibrin specificity, 80-fold reduced binding affinity to the physiological plasminogen activator inhibitor PAI-1 and 6-fold prolonged plasma half-life (22 vs 3.5 minutes).",Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452736/),min,22,110266,DB00009,Alteplase
,12452736,plasma half-life,"Specific mutations at three sites in the alteplase molecule result in 15-fold higher fibrin specificity, 80-fold reduced binding affinity to the physiological plasminogen activator inhibitor PAI-1 and 6-fold prolonged plasma half-life (22 vs 3.5 minutes).",Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452736/),min,3.5,110267,DB00009,Alteplase
,12452736,half-life,"Tenecteplase exhibited biphasic disposition; the initial disposition phase was predominant with a mean half-life of 17-24 minutes, and the mean terminal half-life was 65-132 min.",Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452736/),min,17-24,110268,DB00009,Alteplase
,12452736,terminal half-life,"Tenecteplase exhibited biphasic disposition; the initial disposition phase was predominant with a mean half-life of 17-24 minutes, and the mean terminal half-life was 65-132 min.",Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452736/),min,65-132,110269,DB00009,Alteplase
,12452736,clearance (CL),"Over the clinically relevant dose range of 30-50mg, mean clearance (CL) was 105 ml/min.",Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452736/),[ml] / [min],105,110270,DB00009,Alteplase
,12452736,volume of distribution V(1),"The mean initial volume of distribution V(1) was 4.2-6.3L, approximating plasma volume, and volume of distribution at steady state was 6.1-9.9L, suggesting limited extravascular distribution or binding.",Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452736/),l,4.2-6.3,110271,DB00009,Alteplase
,12452736,volume of distribution at steady state,"The mean initial volume of distribution V(1) was 4.2-6.3L, approximating plasma volume, and volume of distribution at steady state was 6.1-9.9L, suggesting limited extravascular distribution or binding.",Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452736/),l,6.1-9.9,110272,DB00009,Alteplase
exceeded,12452736,partial AUC(2-90),"More than 75% of patients achieved normal flow at 90 minutes after administration when their partial AUC(2-90) exceeded 320 microg.min/ml, corresponding to an average plasma concentration of 3.6 microg/ml.",Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452736/),[min·μg] / [ml],320,110273,DB00009,Alteplase
,31243790,accumulation ratio,"With multiple doses, steady state was achieved by day 7 with minimal accumulation (mean accumulation ratio 1.15-1.25), and the PK was time-independent.","First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31243790/),,1.15-1.25,110788,DB00009,Alteplase
,31243790,terminal half-life,"The mean terminal half-life ranged from 17.2 to 24.9 hours, which was similar to previous intravenous administration data.","First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31243790/),h,17.2 to 24.9,110789,DB00009,Alteplase
,25280819,prothrombin time (PT),"Clinical data on admission were as follows: blood pressure, 170/90 mm Hg; prothrombin time (PT), 22.6 seconds (control, 12.9 seconds); international normalized ratio, 2.03; activated partial thromboplastin time, 46 seconds (normal, 23-32 seconds); and creatinine level, 1.11 mg/dL.",Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280819/),seconds,22.6,111299,DB00009,Alteplase
,25280819,prothrombin time (PT),"Clinical data on admission were as follows: blood pressure, 170/90 mm Hg; prothrombin time (PT), 22.6 seconds (control, 12.9 seconds); international normalized ratio, 2.03; activated partial thromboplastin time, 46 seconds (normal, 23-32 seconds); and creatinine level, 1.11 mg/dL.",Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280819/),seconds,12.9,111300,DB00009,Alteplase
,25280819,international normalized ratio,"Clinical data on admission were as follows: blood pressure, 170/90 mm Hg; prothrombin time (PT), 22.6 seconds (control, 12.9 seconds); international normalized ratio, 2.03; activated partial thromboplastin time, 46 seconds (normal, 23-32 seconds); and creatinine level, 1.11 mg/dL.",Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280819/),,2.03,111301,DB00009,Alteplase
,25280819,activated partial thromboplastin time,"Clinical data on admission were as follows: blood pressure, 170/90 mm Hg; prothrombin time (PT), 22.6 seconds (control, 12.9 seconds); international normalized ratio, 2.03; activated partial thromboplastin time, 46 seconds (normal, 23-32 seconds); and creatinine level, 1.11 mg/dL.",Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280819/),seconds,46,111302,DB00009,Alteplase
over,8236138,plasma half-life,"K2tu-PA, as t-PA has high affinity for fibrin and is activated by fibrin but has a longer plasma half-life (over 30 min).",Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236138/),min,30,113330,DB00009,Alteplase
,8236138,accretion,"The injection of the three increasing doses of rt-PA was followed by an accretion of 54.9 +/- 5.3 micrograms, 49.1 +/- 6.1 micrograms and 47.2 +/- 4.8 micrograms.",Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236138/),μg,54.9,113331,DB00009,Alteplase
,8236138,accretion,"The injection of the three increasing doses of rt-PA was followed by an accretion of 54.9 +/- 5.3 micrograms, 49.1 +/- 6.1 micrograms and 47.2 +/- 4.8 micrograms.",Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236138/),μg,49.1,113332,DB00009,Alteplase
,8236138,accretion,"The injection of the three increasing doses of rt-PA was followed by an accretion of 54.9 +/- 5.3 micrograms, 49.1 +/- 6.1 micrograms and 47.2 +/- 4.8 micrograms.",Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236138/),μg,47.2,113333,DB00009,Alteplase
,21302035,t1/2,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),h,1.5,117383,DB00009,Alteplase
,21302035,t1/2,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),h,1.3,117384,DB00009,Alteplase
,21302035,t1/2,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),h,1.2,117385,DB00009,Alteplase
,21302035,AUC0-t,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),[h·mg] / [l],1.0,117386,DB00009,Alteplase
,21302035,AUC0-t,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),[h·mg] / [l],2.1,117387,DB00009,Alteplase
,21302035,AUC0-t,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),[h·mg] / [l],5.6,117388,DB00009,Alteplase
,21302035,AUC0-∞,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),[h·mg] / [l],1.1,117389,DB00009,Alteplase
,21302035,AUC0-∞,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),[h·mg] / [l],2.1,117390,DB00009,Alteplase
,21302035,AUC0-∞,"The main pharmacokinetic parameters were as follows: geometric mean [95% confidence interval, CI] for t1/2 were 1.5 (1.4, 1.6), 1.3 (1.2, 1.4), and 1.2 (1.2, 1.3) h, AUC0-t were 1.0 (0.7, 1.3), 2.1 (1.5, 2.7), and 5.6 (4.7, 6.6) mg h L(-1), AUC0-∞ were 1.1 (0.8, 1.3), 2.1 (1.5, 2.7), and 5.8 (4.7, 6.7) mg h L(-1) for 10, 20, and 30 mg group, respectively.","Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302035/),[h·mg] / [l],5.8,117391,DB00009,Alteplase
,9459338,half-life,The initial phase had a mean half-life that ranged from 11 +/- 5 to 20 +/- 6 min and was followed by a terminal phase with a mean half-life that ranged from 41 +/- 16 to 138 +/- 84 min.,"Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459338/),min,11,117909,DB00009,Alteplase
,9459338,half-life,The initial phase had a mean half-life that ranged from 11 +/- 5 to 20 +/- 6 min and was followed by a terminal phase with a mean half-life that ranged from 41 +/- 16 to 138 +/- 84 min.,"Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459338/),min,20,117910,DB00009,Alteplase
,9459338,half-life,The initial phase had a mean half-life that ranged from 11 +/- 5 to 20 +/- 6 min and was followed by a terminal phase with a mean half-life that ranged from 41 +/- 16 to 138 +/- 84 min.,"Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459338/),min,41,117911,DB00009,Alteplase
,9459338,half-life,The initial phase had a mean half-life that ranged from 11 +/- 5 to 20 +/- 6 min and was followed by a terminal phase with a mean half-life that ranged from 41 +/- 16 to 138 +/- 84 min.,"Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459338/),min,138,117912,DB00009,Alteplase
,9459338,plasma clearance,"Mean TNK-tPA plasma clearance was 125 +/- 25 - 216 +/- 98 ml/min, and the initial volume of distribution was 4.3 +/- 2 - 8.4 +/- 6 1.","Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459338/),[ml] / [min],125,117913,DB00009,Alteplase
,9459338,plasma clearance,"Mean TNK-tPA plasma clearance was 125 +/- 25 - 216 +/- 98 ml/min, and the initial volume of distribution was 4.3 +/- 2 - 8.4 +/- 6 1.","Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459338/),[ml] / [min],216,117914,DB00009,Alteplase
,9459338,initial volume of distribution,"Mean TNK-tPA plasma clearance was 125 +/- 25 - 216 +/- 98 ml/min, and the initial volume of distribution was 4.3 +/- 2 - 8.4 +/- 6 1.","Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459338/),1,4.3,117915,DB00009,Alteplase
,9459338,initial volume of distribution,"Mean TNK-tPA plasma clearance was 125 +/- 25 - 216 +/- 98 ml/min, and the initial volume of distribution was 4.3 +/- 2 - 8.4 +/- 6 1.","Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459338/),1,8.4,117916,DB00009,Alteplase
,1370924,Steady-state plasma iloprost concentration,Steady-state plasma iloprost concentration was 591 +/- 64 pmol/l.,Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1370924/),[pM] / [l],591,120742,DB00009,Alteplase
,1370924,Steady-state clearance,"Steady-state clearance of t-PA was unchanged by iloprost (454 +/- 65 versus 443 +/- 136 ml/min in controls, p = NS).",Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1370924/),[ml] / [min],454,120743,DB00009,Alteplase
,1370924,Steady-state clearance,"Steady-state clearance of t-PA was unchanged by iloprost (454 +/- 65 versus 443 +/- 136 ml/min in controls, p = NS).",Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1370924/),[ml] / [min],443,120744,DB00009,Alteplase
,3135637,plasma half-lives,The plasma half-lives of lambda 1 and lambda 2 phases of delta 2-89 tPA were 15 minutes and 180 minutes which are significantly higher than those of rtPA.,"Disposition of a novel recombinant tissue plasminogen activator, delta 2-89 TPA, in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3135637/),min,15,123199,DB00009,Alteplase
,3135637,plasma half-lives,The plasma half-lives of lambda 1 and lambda 2 phases of delta 2-89 tPA were 15 minutes and 180 minutes which are significantly higher than those of rtPA.,"Disposition of a novel recombinant tissue plasminogen activator, delta 2-89 TPA, in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3135637/),min,180,123200,DB00009,Alteplase
,3102584,plateau levels,"When both preparations were infused intravenously for 90 minutes at rates of 4 to 11 micrograms/kg per min, plateau levels of the drug in plasma ranged from 0.52 +/- 0.15 to 1.8 +/- 0.4 micrograms/ml and were linearly correlated with the infusion rate.",Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102584/),[μg] / [ml],0.52,125008,DB00009,Alteplase
,3102584,plateau levels,"When both preparations were infused intravenously for 90 minutes at rates of 4 to 11 micrograms/kg per min, plateau levels of the drug in plasma ranged from 0.52 +/- 0.15 to 1.8 +/- 0.4 micrograms/ml and were linearly correlated with the infusion rate.",Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102584/),[μg] / [ml],1.8,125009,DB00009,Alteplase
,3102584,alpha half-life,"For G11021, an alpha half-life of 4.1 to 6.3 minutes, a beta half-life of 41 to 50 minutes, a central compartment volume of 3.5 to 5.4 liters, a total distribution volume of 28 to 44 liters and a plasma clearance of 450 to 640 ml/min.",Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102584/),min,4.1 to 6.3,125010,DB00009,Alteplase
,3102584,beta half-life,"For G11021, an alpha half-life of 4.1 to 6.3 minutes, a beta half-life of 41 to 50 minutes, a central compartment volume of 3.5 to 5.4 liters, a total distribution volume of 28 to 44 liters and a plasma clearance of 450 to 640 ml/min.",Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102584/),min,41 to 50,125011,DB00009,Alteplase
,3102584,central compartment volume,"For G11021, an alpha half-life of 4.1 to 6.3 minutes, a beta half-life of 41 to 50 minutes, a central compartment volume of 3.5 to 5.4 liters, a total distribution volume of 28 to 44 liters and a plasma clearance of 450 to 640 ml/min.",Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102584/),l,3.5 to 5.4,125012,DB00009,Alteplase
,3102584,total distribution volume,"For G11021, an alpha half-life of 4.1 to 6.3 minutes, a beta half-life of 41 to 50 minutes, a central compartment volume of 3.5 to 5.4 liters, a total distribution volume of 28 to 44 liters and a plasma clearance of 450 to 640 ml/min.",Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102584/),l,28 to 44,125013,DB00009,Alteplase
,3102584,plasma clearance,"For G11021, an alpha half-life of 4.1 to 6.3 minutes, a beta half-life of 41 to 50 minutes, a central compartment volume of 3.5 to 5.4 liters, a total distribution volume of 28 to 44 liters and a plasma clearance of 450 to 640 ml/min.",Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102584/),[ml] / [min],450 to 640,125014,DB00009,Alteplase
,3102584,co,A coronary reperfusion rate of 81% (13 of 16 patients) was obtained with 5.3 micrograms/kg per min of G11021 and a rate of 86% (6 of 7 patients) was obtained with 9.4 micrograms/kg per min of G11035.,Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102584/),%,81,125015,DB00009,Alteplase
<,8960425,aPTT,"In 82.5% of the patients, aPTT values were ranged between the highest and the lowest aPTT of < 30 s.",Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8960425/),s,30,125200,DB00009,Alteplase
,8349826,plasma half-life,We found that intravenous administration of purified 39-kD protein to rats prolonged the plasma half-life of 125I-t-PA from 1 min to approximately 5-6 min.,39-kD protein inhibits tissue-type plasminogen activator clearance in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8349826/),min,1,129016,DB00009,Alteplase
,8349826,plasma half-life,We found that intravenous administration of purified 39-kD protein to rats prolonged the plasma half-life of 125I-t-PA from 1 min to approximately 5-6 min.,39-kD protein inhibits tissue-type plasminogen activator clearance in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8349826/),min,5-6,129017,DB00009,Alteplase
,8349826,half-lives,Clearance of 125I-39-kD protein was a biphasic process with half-lives of 30 s and 9 min and the liver was the primary organ of clearance.,39-kD protein inhibits tissue-type plasminogen activator clearance in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8349826/),s,30,129018,DB00009,Alteplase
,8349826,half-lives,Clearance of 125I-39-kD protein was a biphasic process with half-lives of 30 s and 9 min and the liver was the primary organ of clearance.,39-kD protein inhibits tissue-type plasminogen activator clearance in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8349826/),min,9,129019,DB00009,Alteplase
,3370312,t1/2,"A somewhat longer half-life (t1/2) of the one derivative studied was observed in dogs (t1/2, 16 minutes) as compared with the rat (t1/2, five minutes).",Preparation of polyethylene glycol-tissue plasminogen activator adducts that retain functional activity: characteristics and behavior in three animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370312/),min,16,129139,DB00009,Alteplase
,3370312,t1/2,"A somewhat longer half-life (t1/2) of the one derivative studied was observed in dogs (t1/2, 16 minutes) as compared with the rat (t1/2, five minutes).",Preparation of polyethylene glycol-tissue plasminogen activator adducts that retain functional activity: characteristics and behavior in three animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370312/),min,five,129140,DB00009,Alteplase
,8170967,t 1/2,Current treatment with tissue plasminogen activator (tPA) requires an intravenous infusion (1.5-3 h) because the clearance of tPA from the circulation is rapid (t 1/2 approximately 6 min).,A faster-acting and more potent form of tissue plasminogen activator. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8170967/),min,6,133306,DB00009,Alteplase
,3094354,ratio between plateau levels,"The ratio between plateau levels of rt-PA in plasma and infusion rate was inversely related to initial distribution volume (7.3 +/- 2.9 liters, n = 21).","Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094354/),l,7.3,137198,DB00009,Alteplase
,3094354,initial distribution volume,"The ratio between plateau levels of rt-PA in plasma and infusion rate was inversely related to initial distribution volume (7.3 +/- 2.9 liters, n = 21).","Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094354/),l,7.3,137199,DB00009,Alteplase
,3094354,initial,"The initial and terminal half-lives of rt-PA in the blood were 5.3 +/- 1.7 and 46.2 +/- 14 minutes, respectively.","Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094354/),min,5.3,137200,DB00009,Alteplase
,3094354,terminal half-lives,"The initial and terminal half-lives of rt-PA in the blood were 5.3 +/- 1.7 and 46.2 +/- 14 minutes, respectively.","Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094354/),min,46.2,137201,DB00009,Alteplase
,1372625,steady state plasma concentrations,"Mean steady state plasma concentrations of alteplase during the initial 30 min were 3.2 +/- 0.84 micrograms/ml, measured immunochemically, and 2.1 +/- 0.23 micrograms/ml, measured using a functional activity assay.",Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1372625/),[μg] / [ml],3.2,137822,DB00009,Alteplase
,1372625,steady state plasma concentrations,"Mean steady state plasma concentrations of alteplase during the initial 30 min were 3.2 +/- 0.84 micrograms/ml, measured immunochemically, and 2.1 +/- 0.23 micrograms/ml, measured using a functional activity assay.",Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1372625/),[μg] / [ml],2.1,137823,DB00009,Alteplase
,1372625,plasma half-life,"However, the predominant plasma half-life determined by model fitting based on either assay (3.3 to 3.5 min) was unaltered compared with the standard regimen.",Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1372625/),min,3.3 to 3.5,137824,DB00009,Alteplase
,1372625,Maximal concentrations,"Maximal concentrations of fibrin and fibrinogen degradation products were 5.1 +/- 2.2 and 1.9 +/- 1.1 micrograms/ml, respectively.",Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1372625/),[μg] / [ml],5.1,137825,DB00009,Alteplase
,1372625,Maximal concentrations,"Maximal concentrations of fibrin and fibrinogen degradation products were 5.1 +/- 2.2 and 1.9 +/- 1.1 micrograms/ml, respectively.",Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1372625/),[μg] / [ml],1.9,137826,DB00009,Alteplase
,7198302,t 1/2,The disappearance rate of EPA from the plasma could adequately be described by a single exponential term with a t 1/2 of approximately 2 min for both the one-chain and two-chain forms of EPA.,Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198302/),min,2,139220,DB00009,Alteplase
,7198302,t 1/2,"Following intravenous injection of 125I-labeled EPA the radioactivity disappeared rapidly from the plasma also with a t 1/2 of approximately 2 min down to a level of 15 to 20 percent, followed by a small rise of blood radioactivity.",Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198302/),min,2,139221,DB00009,Alteplase
,7649155,specific amidolytic activity,"The purified conjugate obtained has a lower specific amidolytic activity (72,000 U/mg) than unconjugated Cys-delta 125-pro-urikinase (240,000 U/mg) due to its higher molecular mass and has a similar fibrinolytic activity in a clot lysis test to that of delta 125-pro-urokinase.",Prolonged half-life in the circulation of a chemical conjugate between a pro-urokinase derivative and human serum albumin. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649155/),[u] / [mg],"72,000",141623,DB00009,Alteplase
,7649155,specific amidolytic activity,"The purified conjugate obtained has a lower specific amidolytic activity (72,000 U/mg) than unconjugated Cys-delta 125-pro-urikinase (240,000 U/mg) due to its higher molecular mass and has a similar fibrinolytic activity in a clot lysis test to that of delta 125-pro-urokinase.",Prolonged half-life in the circulation of a chemical conjugate between a pro-urokinase derivative and human serum albumin. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649155/),[u] / [mg],"240,000",141624,DB00009,Alteplase
,2453751,peak antigen levels,Injection of 0.15 mg/kg resulted in peak antigen levels in plasma of 1.58 +/- 0.72 micrograms/ml (mean +/- SEM) and caused reperfusion within 14 +/- 6 min.,"Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453751/),[μg] / [ml],1.58,142871,DB00009,Alteplase
,2453751,plasma peak levels,A bolus of 0.038 mg/kg yielded plasma peak levels of 0.43 +/- 0.20 micrograms/ml but did not cause coronary recanalization within 3 h.,"Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453751/),[μg] / [ml],0.43,142872,DB00009,Alteplase
,2453751,plasma peak levels,A bolus injection of natural t-PA (Mel-t-PA) at a dose of 0.1 mg/kg in four dogs resulted in plasma peak levels of 0.46 +/- 0.09 micrograms/ml and caused partial coronary artery reperfusion within 3 h in one of four dogs (after 31 min).,"Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453751/),[μg] / [ml],0.46,142873,DB00009,Alteplase
,2453751,alpha half-life (t1/2),"Pharmacokinetic parameters for t-PA-delta FE3X were alpha half-life (t1/2) 14-18 min, beta t1/2 72-125 min, and plasma clearance 21-36 ml/min.","Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453751/),min,14-18,142874,DB00009,Alteplase
,2453751,beta t1/2,"Pharmacokinetic parameters for t-PA-delta FE3X were alpha half-life (t1/2) 14-18 min, beta t1/2 72-125 min, and plasma clearance 21-36 ml/min.","Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453751/),min,72-125,142875,DB00009,Alteplase
,2453751,plasma clearance,"Pharmacokinetic parameters for t-PA-delta FE3X were alpha half-life (t1/2) 14-18 min, beta t1/2 72-125 min, and plasma clearance 21-36 ml/min.","Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453751/),[ml] / [min],21-36,142876,DB00009,Alteplase
,2453751,Mel-t-PA,"For Mel-t-PA, the corresponding values were 3 min, 8 min, and 520 ml/min.","Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453751/),min,3,142877,DB00009,Alteplase
,2453751,Mel-t-PA,"For Mel-t-PA, the corresponding values were 3 min, 8 min, and 520 ml/min.","Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453751/),min,8,142878,DB00009,Alteplase
,2453751,Mel-t-PA,"For Mel-t-PA, the corresponding values were 3 min, 8 min, and 520 ml/min.","Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453751/),[ml] / [min],520,142879,DB00009,Alteplase
,1899689,half-lives,"The half-lives for t-PA, determined by a two-compartmental pharmacokinetic model, were: alpha, 20.1 minutes, and beta, 120.0 minutes.","Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1899689/),min,20.1,148630,DB00009,Alteplase
,1899689,alpha,"The half-lives for t-PA, determined by a two-compartmental pharmacokinetic model, were: alpha, 20.1 minutes, and beta, 120.0 minutes.","Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1899689/),min,20.1,148631,DB00009,Alteplase
,1899689,beta,"The half-lives for t-PA, determined by a two-compartmental pharmacokinetic model, were: alpha, 20.1 minutes, and beta, 120.0 minutes.","Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1899689/),min,120.0,148632,DB00009,Alteplase
,1899689,alpha,"The corresponding values for t-PA-PAI-1 complex were: alpha, 9.7 minutes, and beta, about 7 hours.","Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1899689/),min,9.7,148633,DB00009,Alteplase
,1899689,beta,"The corresponding values for t-PA-PAI-1 complex were: alpha, 9.7 minutes, and beta, about 7 hours.","Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1899689/),h,7,148634,DB00009,Alteplase
,1899689,k12,"The model microconstants were computed for t-PA and t-PA-PAI-1 complex and the marked difference between the ""on"" microconstants k12 for t-PA (0.026 +/- 0.001 min-1) and t-PA-PAI-1 complex (0.090 +/- 0.025 min-1) suggests that the effect on binding to liver cells is the most important factor in the faster clearance of t-PA-PAI-1 complex when compared with t-PA.","Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1899689/),1/[min],0.026,148635,DB00009,Alteplase
,1899689,k12,"The model microconstants were computed for t-PA and t-PA-PAI-1 complex and the marked difference between the ""on"" microconstants k12 for t-PA (0.026 +/- 0.001 min-1) and t-PA-PAI-1 complex (0.090 +/- 0.025 min-1) suggests that the effect on binding to liver cells is the most important factor in the faster clearance of t-PA-PAI-1 complex when compared with t-PA.","Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1899689/),1/[min],0.090,148636,DB00009,Alteplase
,9008448,plasma clearance,TNK-TPA demonstrated a plasma clearance of 151 +/- 55 mL/min and a half-life of 17 +/- 7 minutes.,TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9008448/),[ml] / [min],151,155220,DB00009,Alteplase
,9008448,half-life,TNK-TPA demonstrated a plasma clearance of 151 +/- 55 mL/min and a half-life of 17 +/- 7 minutes.,TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9008448/),min,17,155221,DB00009,Alteplase
,8820418,clearance,"In comparison with sham surgery, 1-hr clamping plus recovery for 6 days had the least effect on inulin clearance, followed by clamping and recovery for 3 days and bilateral nephrectomy (20.2 +/- 1.8 vs. 13.0 +/- 1.3, 8.3 +/- 0.8, and 3.1 +/- 0.2 ml center dot min-1 center dot kg-1, p < 0.01).",Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820418/),[center·center·dot·dot·ml] / [kg·min],20.2,160239,DB00009,Alteplase
,8820418,clearance,"In comparison with sham surgery, 1-hr clamping plus recovery for 6 days had the least effect on inulin clearance, followed by clamping and recovery for 3 days and bilateral nephrectomy (20.2 +/- 1.8 vs. 13.0 +/- 1.3, 8.3 +/- 0.8, and 3.1 +/- 0.2 ml center dot min-1 center dot kg-1, p < 0.01).",Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820418/),[center·center·dot·dot·ml] / [kg·min],13.0,160240,DB00009,Alteplase
,8820418,clearance,"In comparison with sham surgery, 1-hr clamping plus recovery for 6 days had the least effect on inulin clearance, followed by clamping and recovery for 3 days and bilateral nephrectomy (20.2 +/- 1.8 vs. 13.0 +/- 1.3, 8.3 +/- 0.8, and 3.1 +/- 0.2 ml center dot min-1 center dot kg-1, p < 0.01).",Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820418/),[center·center·dot·dot·ml] / [kg·min],8.3,160241,DB00009,Alteplase
,8820418,clearance,"In comparison with sham surgery, 1-hr clamping plus recovery for 6 days had the least effect on inulin clearance, followed by clamping and recovery for 3 days and bilateral nephrectomy (20.2 +/- 1.8 vs. 13.0 +/- 1.3, 8.3 +/- 0.8, and 3.1 +/- 0.2 ml center dot min-1 center dot kg-1, p < 0.01).",Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820418/),[center·center·dot·dot·ml] / [kg·min],3.1,160242,DB00009,Alteplase
,8820418,Total plasma clearance,"Total plasma clearance of reteplase was significantly reduced, compared with sham surgery after 1-hr clamping plus 3-day recovery and bilateral nephrectomy (3.65 +/- 0.26 vs.",Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820418/),,3.65,160243,DB00009,Alteplase
,24118238,therapeutic concentrations,Estimated therapeutic concentrations of EACA and TEA were significantly lower in horses (5.82; 95% CI 3.77-7.86 μg/mL and 0.512; 95% CI 0.277-0.748 μg/mL) than in humans (113.2; 95% CI 95.8-130.6 μg/mL and 11.4; 95% CI 8.62-14.1 μg/mL).,Therapeutic plasma concentrations of epsilon aminocaproic acid and tranexamic acid in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118238/),[μg] / [ml],5.82,161143,DB00009,Alteplase
,24118238,therapeutic concentrations,Estimated therapeutic concentrations of EACA and TEA were significantly lower in horses (5.82; 95% CI 3.77-7.86 μg/mL and 0.512; 95% CI 0.277-0.748 μg/mL) than in humans (113.2; 95% CI 95.8-130.6 μg/mL and 11.4; 95% CI 8.62-14.1 μg/mL).,Therapeutic plasma concentrations of epsilon aminocaproic acid and tranexamic acid in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118238/),[μg] / [ml],0.512,161144,DB00009,Alteplase
,24118238,therapeutic concentrations,Estimated therapeutic concentrations of EACA and TEA were significantly lower in horses (5.82; 95% CI 3.77-7.86 μg/mL and 0.512; 95% CI 0.277-0.748 μg/mL) than in humans (113.2; 95% CI 95.8-130.6 μg/mL and 11.4; 95% CI 8.62-14.1 μg/mL).,Therapeutic plasma concentrations of epsilon aminocaproic acid and tranexamic acid in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118238/),[μg] / [ml],113.2,161145,DB00009,Alteplase
,24118238,therapeutic concentrations,Estimated therapeutic concentrations of EACA and TEA were significantly lower in horses (5.82; 95% CI 3.77-7.86 μg/mL and 0.512; 95% CI 0.277-0.748 μg/mL) than in humans (113.2; 95% CI 95.8-130.6 μg/mL and 11.4; 95% CI 8.62-14.1 μg/mL).,Therapeutic plasma concentrations of epsilon aminocaproic acid and tranexamic acid in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118238/),[μg] / [ml],11.4,161146,DB00009,Alteplase
,1914379,D-dimers,Fibrin D-dimers were highest with 1147 +/- 380 ng/ml at 5.5 MU of BM 06.022.,Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914379/),[ng] / [ml],1147,163242,DB00009,Alteplase
,1914379,AUC,"At 5.5 MU of BM 06.022, the AUC was 313 +/- 47 IU.hr.ml-1, the total plasma clearance was 306 +/- 40 ml/min, and the half-life was 14.4 +/- 1.1 minutes.",Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914379/),[h·iu] / [ml],313,163243,DB00009,Alteplase
,1914379,total plasma clearance,"At 5.5 MU of BM 06.022, the AUC was 313 +/- 47 IU.hr.ml-1, the total plasma clearance was 306 +/- 40 ml/min, and the half-life was 14.4 +/- 1.1 minutes.",Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914379/),[ml] / [min],306,163244,DB00009,Alteplase
,1914379,half-life,"At 5.5 MU of BM 06.022, the AUC was 313 +/- 47 IU.hr.ml-1, the total plasma clearance was 306 +/- 40 ml/min, and the half-life was 14.4 +/- 1.1 minutes.",Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914379/),min,14.4,163245,DB00009,Alteplase
,9253807,half-life,Intravenously delivered tPA has a half-life of 3-5 minutes.,High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9253807/),min,3-5,166102,DB00009,Alteplase
,9253807,maximum,"Polyethylene glycol conjugated recombinant hirudin (PEG-rH) (0.7 mg/kg) antigen and activity were measurable after just 1 hr, reaching a maximum (663 and 884 ng/ml respectively) at 12 hours.",High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9253807/),[ng] / [ml],663,166103,DB00009,Alteplase
,9253807,maximum,"Polyethylene glycol conjugated recombinant hirudin (PEG-rH) (0.7 mg/kg) antigen and activity were measurable after just 1 hr, reaching a maximum (663 and 884 ng/ml respectively) at 12 hours.",High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9253807/),[ng] / [ml],884,166104,DB00009,Alteplase
,3132929,Cmax,"Highest rt-PA concentrations were measured in ELISA with P PACK-treated samples, yielding the following pharmacokinetic parameters (2-compartment model, mean +/- S.D.): Cmax = 973 +/- 133 ng/ml, CL = 687 ml/min, dominant half-life t1/2 alpha = 3.3 +/- 0.4 min, t1/2 beta = 26 +/- 12 min, V1 = 3.9 +/- 0.6 l and Vss = 7.2 +/- 1.0 l.",Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3132929/),[ng] / [ml],973,166225,DB00009,Alteplase
,3132929,CL,"Highest rt-PA concentrations were measured in ELISA with P PACK-treated samples, yielding the following pharmacokinetic parameters (2-compartment model, mean +/- S.D.): Cmax = 973 +/- 133 ng/ml, CL = 687 ml/min, dominant half-life t1/2 alpha = 3.3 +/- 0.4 min, t1/2 beta = 26 +/- 12 min, V1 = 3.9 +/- 0.6 l and Vss = 7.2 +/- 1.0 l.",Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3132929/),[ml] / [min],687,166226,DB00009,Alteplase
,3132929,half-life t1/2 alpha,"Highest rt-PA concentrations were measured in ELISA with P PACK-treated samples, yielding the following pharmacokinetic parameters (2-compartment model, mean +/- S.D.): Cmax = 973 +/- 133 ng/ml, CL = 687 ml/min, dominant half-life t1/2 alpha = 3.3 +/- 0.4 min, t1/2 beta = 26 +/- 12 min, V1 = 3.9 +/- 0.6 l and Vss = 7.2 +/- 1.0 l.",Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3132929/),min,3.3,166227,DB00009,Alteplase
,3132929,t1/2 beta,"Highest rt-PA concentrations were measured in ELISA with P PACK-treated samples, yielding the following pharmacokinetic parameters (2-compartment model, mean +/- S.D.): Cmax = 973 +/- 133 ng/ml, CL = 687 ml/min, dominant half-life t1/2 alpha = 3.3 +/- 0.4 min, t1/2 beta = 26 +/- 12 min, V1 = 3.9 +/- 0.6 l and Vss = 7.2 +/- 1.0 l.",Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3132929/),min,26,166228,DB00009,Alteplase
,3132929,V1,"Highest rt-PA concentrations were measured in ELISA with P PACK-treated samples, yielding the following pharmacokinetic parameters (2-compartment model, mean +/- S.D.): Cmax = 973 +/- 133 ng/ml, CL = 687 ml/min, dominant half-life t1/2 alpha = 3.3 +/- 0.4 min, t1/2 beta = 26 +/- 12 min, V1 = 3.9 +/- 0.6 l and Vss = 7.2 +/- 1.0 l.",Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3132929/),l,3.9,166229,DB00009,Alteplase
,3132929,Vss,"Highest rt-PA concentrations were measured in ELISA with P PACK-treated samples, yielding the following pharmacokinetic parameters (2-compartment model, mean +/- S.D.): Cmax = 973 +/- 133 ng/ml, CL = 687 ml/min, dominant half-life t1/2 alpha = 3.3 +/- 0.4 min, t1/2 beta = 26 +/- 12 min, V1 = 3.9 +/- 0.6 l and Vss = 7.2 +/- 1.0 l.",Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3132929/),l,7.2,166230,DB00009,Alteplase
,8026028,clearance,The clearance of DSPA (2.3 to 3.5 mL.min-1.kg-1) was lower compared with TPA (11.4 to 20 mL.min-1.kg-1) due to a prolonged terminal half-life.,Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8026028/),[ml] / [kg·min],2.3 to 3.5,166931,DB00009,Alteplase
,8026028,clearance,The clearance of DSPA (2.3 to 3.5 mL.min-1.kg-1) was lower compared with TPA (11.4 to 20 mL.min-1.kg-1) due to a prolonged terminal half-life.,Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8026028/),[ml] / [kg·min],11.4 to 20,166932,DB00009,Alteplase
,1631793,catalytic efficiencies for p,"The specific fibrinolytic activities on fibrin plates were 160,000 +/- 17,000, 210,000 +/- 88,000 and 460,000 +/- 72,000 IU/mg (mean +/- SEM) for rt-PA P47G, K49N, rt-PA and alteplase, respectively, while the catalytic efficiencies for plasminogen activation (k2/Km) in the absence of fibrin were comparable (1.1 to 1.7 x 10(-3) microM-1s-1).","Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1631793/),1/[μM],1.1,168218,DB00009,Alteplase
,1911713,half-maximal concentration [IC50],Clots that had incorporated activated PAI-1 ex vivo were subsequently protected from dissolution in vivo in a dose-responsive manner (half-maximal concentration [IC50] = 4.3 micrograms/ml).,Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911713/),[μg] / [ml],4.3,168550,DB00009,Alteplase
,1911713,IC50,Clot lysis was also inhibited in a dose-responsive manner (IC50 = 58 micrograms/kg) by intravenous bolus delivery of activated PAI-1 to the circulation.,Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911713/),[μg] / [kg],58,168551,DB00009,Alteplase
,1911713,IC50,The clot-protective effects of circulating PAI-1 were correlated with dose-dependent increases in plasma PAI-1 antigen and activity levels and decreases in plasma PA levels (IC50 = 37 micrograms/ml).,Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911713/),[μg] / [ml],37,168552,DB00009,Alteplase
,1911713,half-life,"Activated and latent PAI-1 was cleared from the circulation in a monophasic manner, with a half-life of approximately 32 and 7 minutes, respectively.",Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911713/),min,32,168553,DB00009,Alteplase
,1911713,half-life,"Activated and latent PAI-1 was cleared from the circulation in a monophasic manner, with a half-life of approximately 32 and 7 minutes, respectively.",Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911713/),min,7,168554,DB00009,Alteplase
,29194320,Peak serum levels,Peak serum levels of TXA after IV and IO administration show concentrations of 160.9 μg/mL and 132.57 μg/mL respectively (p = 0.053).,"No intravenous access, no problem: Intraosseous administration of tranexamic acid is as effective as intravenous in a porcine hemorrhage model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194320/),[μg] / [ml],160.9,170221,DB00009,Alteplase
,29194320,Peak serum levels,Peak serum levels of TXA after IV and IO administration show concentrations of 160.9 μg/mL and 132.57 μg/mL respectively (p = 0.053).,"No intravenous access, no problem: Intraosseous administration of tranexamic acid is as effective as intravenous in a porcine hemorrhage model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194320/),[μg] / [ml],132.57,170222,DB00009,Alteplase
,31389905,absolute bioavailability,The absolute bioavailability of IM TXA was 97%.,Pharmacokinetics of Tranexamic Acid Given as an Intramuscular Injection Compared to Intravenous Infusion in a Swine Model of Ongoing Hemorrhage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31389905/),%,97,170477,DB00009,Alteplase
,9364993,IC50,"In this report we show that dextran 40 and dextran 70 were able to inhibit t-PA binding to the isolated human mannose receptor (IC50 14 and 4 mg/ml, respectively).",Inhibition of mannose receptor-mediated clearance of tissue-type plasminogen activator (t-PA) by dextran: a new explanation for its antithrombotic effect. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9364993/),[mg] / [ml],14,171684,DB00009,Alteplase
,9364993,IC50,"In this report we show that dextran 40 and dextran 70 were able to inhibit t-PA binding to the isolated human mannose receptor (IC50 14 and 4 mg/ml, respectively).",Inhibition of mannose receptor-mediated clearance of tissue-type plasminogen activator (t-PA) by dextran: a new explanation for its antithrombotic effect. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9364993/),[mg] / [ml],4,171685,DB00009,Alteplase
,9364993,IC50,"Both glucose-polymers inhibited mannose receptor-mediated t-PA degradation by human monocyte-derived macrophages in vitro (IC50 7 and 2 mg/ml, respectively).",Inhibition of mannose receptor-mediated clearance of tissue-type plasminogen activator (t-PA) by dextran: a new explanation for its antithrombotic effect. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9364993/),[mg] / [ml],7,171686,DB00009,Alteplase
,9364993,IC50,"Both glucose-polymers inhibited mannose receptor-mediated t-PA degradation by human monocyte-derived macrophages in vitro (IC50 7 and 2 mg/ml, respectively).",Inhibition of mannose receptor-mediated clearance of tissue-type plasminogen activator (t-PA) by dextran: a new explanation for its antithrombotic effect. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9364993/),[mg] / [ml],2,171687,DB00009,Alteplase
,1901531,Time to lysis,"Time to lysis averaged 54 +/- 26 (means +/- SD) minutes and 64 +/- 34 minutes with Hybrid-B and t-PA, respectively (p = NS).","Induction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1901531/),min,54,172130,DB00009,Alteplase
,1901531,Time to lysis,"Time to lysis averaged 54 +/- 26 (means +/- SD) minutes and 64 +/- 34 minutes with Hybrid-B and t-PA, respectively (p = NS).","Induction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1901531/),min,64,172131,DB00009,Alteplase
,1901531,time to lysis,"When Hybrid-B was administered as a bolus (20 mg over 1 minute) to induce a high initial concentration in blood, time to lysis was shortened markedly and averaged 15 +/- 5 minutes.","Induction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1901531/),min,15,172132,DB00009,Alteplase
,1901531,time to reocclusion,"Dogs given Hybrid-B by either infusion or bolus exhibited prolonged time to reocclusion (337 +/- 192 minutes compared with 192 +/- 125 minutes in dogs given t-PA, p less than 0.03), reflecting maintenance of a subthrombolytic but persistently active concentration of activator in blood.","Induction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1901531/),min,337,172133,DB00009,Alteplase
,1901531,time to reocclusion,"Dogs given Hybrid-B by either infusion or bolus exhibited prolonged time to reocclusion (337 +/- 192 minutes compared with 192 +/- 125 minutes in dogs given t-PA, p less than 0.03), reflecting maintenance of a subthrombolytic but persistently active concentration of activator in blood.","Induction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1901531/),min,192,172134,DB00009,Alteplase
,11137937,maximum level,"After 15 minutes of fibrinolytic perfusion, the level of tPA in the perfusion solution was 10,427 +/- 4432 ng/mL, and after 30 minutes the maximum level of 19,726 +/- 5630 ng/mL was reached.",Pharmacokinetics of tissue plasminogen activator in an isolated extracorporeal circuit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11137937/),[ng] / [ml],"19,726",176366,DB00009,Alteplase
,11137937,concentrations,"After 60 minutes when the perfusion was discontinued, tPA concentrations dropped to 15,931 +/- 4818 ng/mL.",Pharmacokinetics of tissue plasminogen activator in an isolated extracorporeal circuit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11137937/),[ng] / [ml],"15,931",176367,DB00009,Alteplase
<,33248975,maximum lysis,Tranexamic acid plasma concentration of >10 μg/mL and maximum lysis of <17% were defined as therapeutic targets independent to the current study.,Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33248975/),%,17,177420,DB00009,Alteplase
,33248975,blood loss,"Median estimated blood loss for cohorts receiving 5, 10, or 15 mg/kg tranexamic acid was 750, 750, and 700 mL, respectively.",Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33248975/),ml,750,177421,DB00009,Alteplase
,33248975,blood loss,"Median estimated blood loss for cohorts receiving 5, 10, or 15 mg/kg tranexamic acid was 750, 750, and 700 mL, respectively.",Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33248975/),ml,700,177422,DB00009,Alteplase
,2450222,maximal plasma levels,After infusion of 0.25 mg rt-PA/kg bw mean maximal plasma levels were 970 +/- 130 ng/ml.,[Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2450222/),[ng] / [ml],970,187548,DB00009,Alteplase
,2450222,half lives of t1/2 alpha,The elimination of rt-PA from plasma was fitted to a two compartment model and was characterized by two half lives of t1/2 alpha = 3.3 and t1/2 beta = 26 minutes.,[Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2450222/),min,3.3,187549,DB00009,Alteplase
,2450222,t1/2 beta,The elimination of rt-PA from plasma was fitted to a two compartment model and was characterized by two half lives of t1/2 alpha = 3.3 and t1/2 beta = 26 minutes.,[Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2450222/),min,26,187550,DB00009,Alteplase
,1905070,c,"Deletion of the finger and growth factor domains in rt-PA (rt-PA-delta FE) was not associated with marked alteration of the thrombolytic potency (c = 90 +/- 30%, b = 0.34 +/- 0.35 mg/kg, and z = 54 +/- 14% per mg/kg), but was associated with a significant reduction of the specific thrombolytic activity.","Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905070/),%,90,195494,DB00009,Alteplase
,1905070,b,"Deletion of the finger and growth factor domains in rt-PA (rt-PA-delta FE) was not associated with marked alteration of the thrombolytic potency (c = 90 +/- 30%, b = 0.34 +/- 0.35 mg/kg, and z = 54 +/- 14% per mg/kg), but was associated with a significant reduction of the specific thrombolytic activity.","Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905070/),[mg] / [kg],0.34,195495,DB00009,Alteplase
,1905070,z,"Deletion of the finger and growth factor domains in rt-PA (rt-PA-delta FE) was not associated with marked alteration of the thrombolytic potency (c = 90 +/- 30%, b = 0.34 +/- 0.35 mg/kg, and z = 54 +/- 14% per mg/kg), but was associated with a significant reduction of the specific thrombolytic activity.","Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905070/),[%] / [kg·mg],54,195496,DB00009,Alteplase
,2483703,elimination half-life,The anti FXa elimination half-life was close to 3 hours.,Study of a new low molecular weight heparin (LU 47311) administered to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2483703/),h,3,203029,DB00009,Alteplase
,1815534,plasma half-life,"The dominant plasma half-life of rt-PA in myocardial infarction patients is short (3.6 min), which allows excellent control of plasma levels during therapy.",Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815534/),min,3.6,205465,DB00009,Alteplase
,1815534,Steady-state plasma concentrations,Steady-state plasma concentrations effecting coronary thrombolysis using the current dosage regimen are 2.2 micrograms/ml.,Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815534/),[μg] / [ml],2.2,205466,DB00009,Alteplase
,1815534,Km,"Clearance of rt-PA can be saturated in animals at very high plasma concentrations (Km = 12-15 micrograms/ml), however, pharmacokinetics in clinical settings are linear.",Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815534/),[μg] / [ml],12-15,205467,DB00009,Alteplase
,3120823,initial t1/2,"After the end of the infusion, t-PA-related antigen disappeared from plasma with an initial t1/2 of four minutes for Mel-t-PA, 25 minutes for t-PA-delta FE, 42 minutes for t-PA-delta FE1X, and 14 minutes for t-PA-delta FE3X.",Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120823/),min,four,209258,DB00009,Alteplase
,3120823,initial t1/2,"After the end of the infusion, t-PA-related antigen disappeared from plasma with an initial t1/2 of four minutes for Mel-t-PA, 25 minutes for t-PA-delta FE, 42 minutes for t-PA-delta FE1X, and 14 minutes for t-PA-delta FE3X.",Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120823/),min,25,209259,DB00009,Alteplase
,3120823,initial t1/2,"After the end of the infusion, t-PA-related antigen disappeared from plasma with an initial t1/2 of four minutes for Mel-t-PA, 25 minutes for t-PA-delta FE, 42 minutes for t-PA-delta FE1X, and 14 minutes for t-PA-delta FE3X.",Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120823/),min,42,209260,DB00009,Alteplase
,3120823,initial t1/2,"After the end of the infusion, t-PA-related antigen disappeared from plasma with an initial t1/2 of four minutes for Mel-t-PA, 25 minutes for t-PA-delta FE, 42 minutes for t-PA-delta FE1X, and 14 minutes for t-PA-delta FE3X.",Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120823/),min,14,209261,DB00009,Alteplase
,4057083,Steady-state plasma concentrations,Steady-state plasma concentrations of 0.9 to 1.6 micrograms/ml were reached.,Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057083/),[μg] / [ml],0.9 to 1.6,212480,DB00009,Alteplase
,4057083,fractional efflux rate constant from the central compartment,The fractional efflux rate constant from the central compartment was 0.10 per min and the fractional catabolic rate constant about 0.02 per min.,Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057083/),1/[min],0.10,212481,DB00009,Alteplase
,4057083,fractional catabolic rate constant,The fractional efflux rate constant from the central compartment was 0.10 per min and the fractional catabolic rate constant about 0.02 per min.,Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057083/),1/[min],0.02,212482,DB00009,Alteplase
,4057083,initial half-life,After cessation of infusion the initial half-life of the drug in plasma was 6 min.,Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057083/),min,6,212483,DB00009,Alteplase
,28223717,elimination half-life (t1/2),The elimination half-life (t1/2) of mt-PA was in the range of 19.1-26.1 min in three doses while that of Alteplase was 8.3 min.,Scale up and pharmacokinetic study of a novel mutated chimeric tissue plasminogen activator (mt-PA) in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223717/),min,19.1-26.1,219281,DB00009,Alteplase
,28223717,elimination half-life (t1/2),The elimination half-life (t1/2) of mt-PA was in the range of 19.1-26.1 min in three doses while that of Alteplase was 8.3 min.,Scale up and pharmacokinetic study of a novel mutated chimeric tissue plasminogen activator (mt-PA) in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223717/),min,8.3,219282,DB00009,Alteplase
,28223717,plasma clearance (CLp),"The plasma clearance (CLp) of mt-PA ranged from 3.8 to 5.9 mL/min in three doses, which was several times lower than that of Alteplase (142.6 mL/min).",Scale up and pharmacokinetic study of a novel mutated chimeric tissue plasminogen activator (mt-PA) in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223717/),[ml] / [min],3.8 to 5.9,219283,DB00009,Alteplase
,28223717,plasma clearance (CLp),"The plasma clearance (CLp) of mt-PA ranged from 3.8 to 5.9 mL/min in three doses, which was several times lower than that of Alteplase (142.6 mL/min).",Scale up and pharmacokinetic study of a novel mutated chimeric tissue plasminogen activator (mt-PA) in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223717/),[ml] / [min],142.6,219284,DB00009,Alteplase
,28223717,mean residence time (MRT),"The mean residence time (MRT) of mt-PA ranged from 23.3-31.8 min in three doses, which was 4-5 times greater than that of Alteplase (6 min).",Scale up and pharmacokinetic study of a novel mutated chimeric tissue plasminogen activator (mt-PA) in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223717/),min,23.3-31.8,219285,DB00009,Alteplase
,28223717,mean residence time (MRT),"The mean residence time (MRT) of mt-PA ranged from 23.3-31.8 min in three doses, which was 4-5 times greater than that of Alteplase (6 min).",Scale up and pharmacokinetic study of a novel mutated chimeric tissue plasminogen activator (mt-PA) in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223717/),min,6,219286,DB00009,Alteplase
,1725068,Half-life,"Half-life of BM 06.022-activity was 11.2 +/- 0.4 min and of antigen was 13.9 +/- 0.7 min, followed by a terminal half-life only for antigen of 173 +/- 33 min.",Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725068/),min,11.2,223487,DB00009,Alteplase
,1725068,Half-life,"Half-life of BM 06.022-activity was 11.2 +/- 0.4 min and of antigen was 13.9 +/- 0.7 min, followed by a terminal half-life only for antigen of 173 +/- 33 min.",Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725068/),min,13.9,223488,DB00009,Alteplase
,1725068,terminal half-life,"Half-life of BM 06.022-activity was 11.2 +/- 0.4 min and of antigen was 13.9 +/- 0.7 min, followed by a terminal half-life only for antigen of 173 +/- 33 min.",Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725068/),min,173,223489,DB00009,Alteplase
,1725068,Plasma clearance,Plasma clearance of BM 06.022 was 371 +/- 13 ml/min for activity and 183 +/- 15 ml/min for antigen.,Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725068/),[ml] / [min],371,223490,DB00009,Alteplase
,1725068,Plasma clearance,Plasma clearance of BM 06.022 was 371 +/- 13 ml/min for activity and 183 +/- 15 ml/min for antigen.,Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725068/),[ml] / [min],183,223491,DB00009,Alteplase
,23468049,half-life,"The half-life of tPA was extended from 7 to 103 and 141 min for non-pegylated and pegylated liposomes, respectively.",Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23468049/),min,7 to 103,226114,DB00009,Alteplase
,23468049,half-life,"The half-life of tPA was extended from 7 to 103 and 141 min for non-pegylated and pegylated liposomes, respectively.",Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23468049/),min,141,226115,DB00009,Alteplase
,1914361,Clearance,Clearance of t-PA activity was 1020 +/- 465 (mean +/- SD) ml/min in phase I and 1359 +/- 590 ml/min in phase II.,"The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914361/),[ml] / [min],1020,226563,DB00009,Alteplase
,1914361,Clearance,Clearance of t-PA activity was 1020 +/- 465 (mean +/- SD) ml/min in phase I and 1359 +/- 590 ml/min in phase II.,"The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914361/),[ml] / [min],1359,226564,DB00009,Alteplase
,1914361,Clearance,Clearance of t-PA antigen was 666 +/- 230 ml/min in phase I and 704 +/- 199 ml/min in phase II.,"The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914361/),[ml] / [min],666,226565,DB00009,Alteplase
,1914361,Clearance,Clearance of t-PA antigen was 666 +/- 230 ml/min in phase I and 704 +/- 199 ml/min in phase II.,"The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914361/),[ml] / [min],704,226566,DB00009,Alteplase
,21545481,total systemic clearance (CL(t)),Lanoteplase mean total systemic clearance (CL(t)) values ranged from 1.9 to 2.8 l h(-1) and mean steady-state volume of distribution (V(ss)) values ranged from 12.3 to 15.6 l.,"The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545481/),[l] / [h],1.9 to 2.8,232735,DB00009,Alteplase
,21545481,steady-state volume of distribution (V(ss)),Lanoteplase mean total systemic clearance (CL(t)) values ranged from 1.9 to 2.8 l h(-1) and mean steady-state volume of distribution (V(ss)) values ranged from 12.3 to 15.6 l.,"The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545481/),l,12.3 to 15.6,232736,DB00009,Alteplase
,2464103,residual,"In vehicle-treated animals, residual thrombus wet weight, determined at the end of the experiment, was 30 +/- 4 mg (mean +/- SEM, n = 8) and spontaneous reperfusion did not occur.",Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2464103/),mg,30,236073,DB00009,Alteplase
,2464103,wet weight,"In vehicle-treated animals, residual thrombus wet weight, determined at the end of the experiment, was 30 +/- 4 mg (mean +/- SEM, n = 8) and spontaneous reperfusion did not occur.",Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2464103/),mg,30,236074,DB00009,Alteplase
,2464103,pool,"The postdosing elimination half-life (t1/2 alpha) did not differ significantly at any dose of rt-PA, and the pooled half-life (t1/2 alpha) for all doses of rt-PA was 2.36 +/- 0.12 min (n = 19).",Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2464103/),min,2.36,236075,DB00009,Alteplase
,10192753,oral bioavailability,Point estimates for the oral bioavailability of PPS were in the range of 0% with small confidence intervals (CIs).,The oral bioavailability of pentosan polysulphate sodium in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10192753/),%,0,236214,DB00009,Alteplase
,4008166,labeling efficiency,"The labeling efficiency was 91.7% for the H-UK, and 90.4% for the L-UK, respectively.",In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008166/),%,91.7,251089,DB00009,Alteplase
,4008166,labeling efficiency,"The labeling efficiency was 91.7% for the H-UK, and 90.4% for the L-UK, respectively.",In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008166/),%,90.4,251090,DB00009,Alteplase
,4008166,half-life,Studies on the in vivo behavior of the 67Ga labeled UK in rabbits showed a very rapid blood clearance with half-life of 4 min (67Ga-DF-L-UK) to 8 min (67Ga-DF-H-UK).,In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008166/),min,4,251091,DB00009,Alteplase
,4008166,half-life,Studies on the in vivo behavior of the 67Ga labeled UK in rabbits showed a very rapid blood clearance with half-life of 4 min (67Ga-DF-L-UK) to 8 min (67Ga-DF-H-UK).,In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008166/),min,8,251092,DB00009,Alteplase
,4008166,activity ratios,"Studies carried out in rabbits with induced thrombi in the femoral vein showed thrombus-to-blood 67Ga-DF-UK activity ratios, 2h after injection, of 2.00-3.08 for the H-UK, and 0.84-1.65 for the L-UK, respectively, with thrombi aged 4 to 3 days.",In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008166/),,2.00-3.08,251093,DB00009,Alteplase
,4008166,activity ratios,"Studies carried out in rabbits with induced thrombi in the femoral vein showed thrombus-to-blood 67Ga-DF-UK activity ratios, 2h after injection, of 2.00-3.08 for the H-UK, and 0.84-1.65 for the L-UK, respectively, with thrombi aged 4 to 3 days.",In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008166/),,0.84-1.65,251094,DB00009,Alteplase
,2898333,t1/2,"Upon cessation of infusion, active tPA plasma concentrations declined rapidly with a t1/2 of 2-3 min.",Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898333/),min,2-3,256325,DB00009,Alteplase
,2898333,systemic clearance,"The systemic clearance ranged from 15-16 ml/min/kg at doses of 0.5-4 micrograms/kg/min, but decreased to 11.7 ml/min/kg at the 8 micrograms/kg/min dose.",Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898333/),[ml] / [kg·min],15-16,256326,DB00009,Alteplase
,2898333,systemic clearance,"The systemic clearance ranged from 15-16 ml/min/kg at doses of 0.5-4 micrograms/kg/min, but decreased to 11.7 ml/min/kg at the 8 micrograms/kg/min dose.",Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898333/),[ml] / [kg·min],11.7,256327,DB00009,Alteplase
,2898333,t1/2,The postinfusion t1/2 of the tPA antigen was considerably longer (13.46 +/- 5.94 min) than that of active tPA.,Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898333/),min,13.46,256328,DB00009,Alteplase
,2503283,clearance (antigen),"Mean clearance (antigen) was 620 +/- 70 (SD) ml/min, volume of distribution at steady state was 8.1 +/- 0.8 L, initial volume of distribution was 4.4 +/- 0.6 L, and dominant half-life was 4.4 +/- 0.3 minutes.",Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503283/),[ml] / [min],620,257366,DB00009,Alteplase
,2503283,volume of distribution at steady state,"Mean clearance (antigen) was 620 +/- 70 (SD) ml/min, volume of distribution at steady state was 8.1 +/- 0.8 L, initial volume of distribution was 4.4 +/- 0.6 L, and dominant half-life was 4.4 +/- 0.3 minutes.",Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503283/),l,8.1,257367,DB00009,Alteplase
,2503283,initial volume of distribution,"Mean clearance (antigen) was 620 +/- 70 (SD) ml/min, volume of distribution at steady state was 8.1 +/- 0.8 L, initial volume of distribution was 4.4 +/- 0.6 L, and dominant half-life was 4.4 +/- 0.3 minutes.",Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503283/),l,4.4,257368,DB00009,Alteplase
,2503283,dominant half-life,"Mean clearance (antigen) was 620 +/- 70 (SD) ml/min, volume of distribution at steady state was 8.1 +/- 0.8 L, initial volume of distribution was 4.4 +/- 0.6 L, and dominant half-life was 4.4 +/- 0.3 minutes.",Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503283/),min,4.4,257369,DB00009,Alteplase
,2120422,Km,"Elimination of t-PA was saturable, with Km = 12-15 micrograms/ml and Vmax = 200-350 micrograms/ml/hr in vivo.",Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120422/),[μg] / [ml],12-15,257702,DB00009,Alteplase
,2120422,Vmax,"Elimination of t-PA was saturable, with Km = 12-15 micrograms/ml and Vmax = 200-350 micrograms/ml/hr in vivo.",Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120422/),[μg] / [h·ml],200-350,257703,DB00009,Alteplase
,2120422,Km,"In isolated rat liver, t-PA elimination capacity was considerably reduced, with Km = 1.5 micrograms/ml and Vmax = 3.7 micrograms/ml/hr.",Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120422/),[μg] / [ml],1.5,257704,DB00009,Alteplase
,2120422,Vmax,"In isolated rat liver, t-PA elimination capacity was considerably reduced, with Km = 1.5 micrograms/ml and Vmax = 3.7 micrograms/ml/hr.",Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120422/),[μg] / [h·ml],3.7,257705,DB00009,Alteplase
,2120422,plasma clearance,"At nonsaturating doses, plasma clearance in vivo was 18-23 ml/min/kg and the dominant half-life was 1.1-2.4 min, compared with 8 ml/min/kg and 4.4 min, respectively, in humans; rat liver perfusate clearance was 0.29 ml/min/g.",Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120422/),[ml] / [kg·min],18-23,257706,DB00009,Alteplase
,2120422,liver perfusate clearance,"At nonsaturating doses, plasma clearance in vivo was 18-23 ml/min/kg and the dominant half-life was 1.1-2.4 min, compared with 8 ml/min/kg and 4.4 min, respectively, in humans; rat liver perfusate clearance was 0.29 ml/min/g.",Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120422/),[ml] / [g·min],0.29,257707,DB00009,Alteplase
,1719279,re,Comparison with infusion experiments showed that intravenous bolus injection of 140 kU/kg of BM 06.022 was equieffective to a 90-min infusion of 800 kU/kg (= 1 mg/kg) of alteplase as a standard treatment regarding reperfusion rate (66%) and time to reperfusion (15 +/- 6 vs. 18 +/- 8 min).,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),,66,258779,DB00009,Alteplase
,1719279,time to reperfusion,Comparison with infusion experiments showed that intravenous bolus injection of 140 kU/kg of BM 06.022 was equieffective to a 90-min infusion of 800 kU/kg (= 1 mg/kg) of alteplase as a standard treatment regarding reperfusion rate (66%) and time to reperfusion (15 +/- 6 vs. 18 +/- 8 min).,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),min,15,258780,DB00009,Alteplase
,1719279,time to reperfusion,Comparison with infusion experiments showed that intravenous bolus injection of 140 kU/kg of BM 06.022 was equieffective to a 90-min infusion of 800 kU/kg (= 1 mg/kg) of alteplase as a standard treatment regarding reperfusion rate (66%) and time to reperfusion (15 +/- 6 vs. 18 +/- 8 min).,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),min,18,258781,DB00009,Alteplase
,1719279,total plasma clearance,Pharmacokinetic analysis for functionally active BM 06.022 or alteplase in plasma revealed a total plasma clearance of 4.1-6.6 ml/min/kg for BM 06.022 and of 12.6-42.3 ml/min/kg for alteplase.,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),[ml] / [kg·min],4.1-6.6,258782,DB00009,Alteplase
,1719279,total plasma clearance,Pharmacokinetic analysis for functionally active BM 06.022 or alteplase in plasma revealed a total plasma clearance of 4.1-6.6 ml/min/kg for BM 06.022 and of 12.6-42.3 ml/min/kg for alteplase.,Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719279/),[ml] / [kg·min],12.6-42.3,258783,DB00009,Alteplase
,1905593,half-life,The clearance of Bat-PA from rabbits exhibited biexponential elimination kinetics; approximately 80% was cleared by the relatively slow beta phase (half-life of 17.1 minutes).,Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905593/),min,17.1,259145,DB00009,Alteplase
,3134000,half-life,"In eyes without an intravitreal fibrin clot, the estimated half-life for t-PA was 4.3 hours by SOFIA and 5.8 hours by ELISA.",Intravitreal clearance of tissue plasminogen activator in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134000/),h,4.3,260064,DB00009,Alteplase
,3134000,half-life,"In eyes without an intravitreal fibrin clot, the estimated half-life for t-PA was 4.3 hours by SOFIA and 5.8 hours by ELISA.",Intravitreal clearance of tissue plasminogen activator in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134000/),h,5.8,260065,DB00009,Alteplase
,3134000,half-life,"In eyes containing a vitreal fibrin clot, the half-life increased to 9.8 hours by SOFIA and 11.9 hours by ELISA.",Intravitreal clearance of tissue plasminogen activator in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134000/),h,9.8,260066,DB00009,Alteplase
,3134000,half-life,"In eyes containing a vitreal fibrin clot, the half-life increased to 9.8 hours by SOFIA and 11.9 hours by ELISA.",Intravitreal clearance of tissue plasminogen activator in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134000/),h,11.9,260067,DB00009,Alteplase
,11315107,Half-lives in the beta phase,"Half-lives in the beta phase were 1.25 and 0.78 h, and AUCs were 507.9 and 286.4 ng.h.ml(-1) respectively.","Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11315107/),h,1.25,260491,DB00009,Alteplase
,11315107,Half-lives in the beta phase,"Half-lives in the beta phase were 1.25 and 0.78 h, and AUCs were 507.9 and 286.4 ng.h.ml(-1) respectively.","Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11315107/),h,0.78,260492,DB00009,Alteplase
,11315107,AUCs,"Half-lives in the beta phase were 1.25 and 0.78 h, and AUCs were 507.9 and 286.4 ng.h.ml(-1) respectively.","Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11315107/),[h·ng] / [ml],507.9,260493,DB00009,Alteplase
,11315107,AUCs,"Half-lives in the beta phase were 1.25 and 0.78 h, and AUCs were 507.9 and 286.4 ng.h.ml(-1) respectively.","Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11315107/),[h·ng] / [ml],286.4,260494,DB00009,Alteplase
,2508258,peak plasma concentration,"Ten mg rt-PA were infused in 2 minutes resulting in a peak plasma concentration (mean +/- SD) of 3310 +/- 950 ng/ml, followed by 50 mg in 1 h and 30 mg in 1.5 h yielding steady state plasma levels of 2210 +/- 470 ng/ml and 930 +/- 200 ng/ml, respectively.",Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2508258/),[ng] / [ml],3310,264754,DB00009,Alteplase
,2508258,steady state plasma levels,"Ten mg rt-PA were infused in 2 minutes resulting in a peak plasma concentration (mean +/- SD) of 3310 +/- 950 ng/ml, followed by 50 mg in 1 h and 30 mg in 1.5 h yielding steady state plasma levels of 2210 +/- 470 ng/ml and 930 +/- 200 ng/ml, respectively.",Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2508258/),[ng] / [ml],2210,264755,DB00009,Alteplase
,2508258,steady state plasma levels,"Ten mg rt-PA were infused in 2 minutes resulting in a peak plasma concentration (mean +/- SD) of 3310 +/- 950 ng/ml, followed by 50 mg in 1 h and 30 mg in 1.5 h yielding steady state plasma levels of 2210 +/- 470 ng/ml and 930 +/- 200 ng/ml, respectively.",Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2508258/),[ng] / [ml],930,264756,DB00009,Alteplase
,2508258,Total clearance,"Total clearance of rt-PA was 380 +/- 74 ml/min, t1/2 alpha was 3.6 +/- 0.9 min and t1/2 beta was 16 +/- 5.4 min.",Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2508258/),[ml] / [min],380,264757,DB00009,Alteplase
,2508258,t1/2 alpha,"Total clearance of rt-PA was 380 +/- 74 ml/min, t1/2 alpha was 3.6 +/- 0.9 min and t1/2 beta was 16 +/- 5.4 min.",Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2508258/),min,3.6,264758,DB00009,Alteplase
,2508258,t1/2 beta,"Total clearance of rt-PA was 380 +/- 74 ml/min, t1/2 alpha was 3.6 +/- 0.9 min and t1/2 beta was 16 +/- 5.4 min.",Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2508258/),min,16,264759,DB00009,Alteplase
,9264480,t(1/2),alpha-Phase clearance of total TPA antigen was faster in subjects with low PAI-1 (t(1/2) of 3.5+/-0.7 minutes) versus high PAI-1 (t(1/2) of 5.3+/-0.9 minutes) (P=.006).,Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9264480/),min,3.5,264854,DB00009,Alteplase
,9264480,t(1/2),alpha-Phase clearance of total TPA antigen was faster in subjects with low PAI-1 (t(1/2) of 3.5+/-0.7 minutes) versus high PAI-1 (t(1/2) of 5.3+/-0.9 minutes) (P=.006).,Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9264480/),min,5.3,264855,DB00009,Alteplase
,9264480,hepatic clearance fraction,"The average hepatic clearance fraction in the two-compartment model was greater for active TPA (89+/-10%, t(1/2) of 2.4+/-0.3 minutes) than for TPA/PAI-1 complex (48+/-17%, t(1/2) of 5.0+/-1.8 minutes) (P=.0006).",Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9264480/),%,89,264856,DB00009,Alteplase
,9264480,t(1/2),"The average hepatic clearance fraction in the two-compartment model was greater for active TPA (89+/-10%, t(1/2) of 2.4+/-0.3 minutes) than for TPA/PAI-1 complex (48+/-17%, t(1/2) of 5.0+/-1.8 minutes) (P=.0006).",Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9264480/),min,2.4,264857,DB00009,Alteplase
,9264480,t(1/2),"The average hepatic clearance fraction in the two-compartment model was greater for active TPA (89+/-10%, t(1/2) of 2.4+/-0.3 minutes) than for TPA/PAI-1 complex (48+/-17%, t(1/2) of 5.0+/-1.8 minutes) (P=.0006).",Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9264480/),min,5.0,264858,DB00009,Alteplase
,23938183,Cmax,The 1 mg/kg dose yielded the following pharmacokinetic parameters: Cmax = 1.25 ± 0.27 μg/ml; CL = 21.46 ± 5.67 ml/min/kg; dominant half life (t1/2α) = 6.81 ± 1.48 minutes; median elimination half life (t1/2β) = 171 min (range: 85–1061); AUC = 50.33 ± 17.62 μg · min /ml.,Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23938183/),[μg] / [ml],1.25,267719,DB00009,Alteplase
,23938183,CL,The 1 mg/kg dose yielded the following pharmacokinetic parameters: Cmax = 1.25 ± 0.27 μg/ml; CL = 21.46 ± 5.67 ml/min/kg; dominant half life (t1/2α) = 6.81 ± 1.48 minutes; median elimination half life (t1/2β) = 171 min (range: 85–1061); AUC = 50.33 ± 17.62 μg · min /ml.,Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23938183/),[ml] / [kg·min],21.46,267720,DB00009,Alteplase
,23938183,dominant half life (t1/2α),The 1 mg/kg dose yielded the following pharmacokinetic parameters: Cmax = 1.25 ± 0.27 μg/ml; CL = 21.46 ± 5.67 ml/min/kg; dominant half life (t1/2α) = 6.81 ± 1.48 minutes; median elimination half life (t1/2β) = 171 min (range: 85–1061); AUC = 50.33 ± 17.62 μg · min /ml.,Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23938183/),min,6.81,267721,DB00009,Alteplase
,23938183,elimination half life (t1/2β),The 1 mg/kg dose yielded the following pharmacokinetic parameters: Cmax = 1.25 ± 0.27 μg/ml; CL = 21.46 ± 5.67 ml/min/kg; dominant half life (t1/2α) = 6.81 ± 1.48 minutes; median elimination half life (t1/2β) = 171 min (range: 85–1061); AUC = 50.33 ± 17.62 μg · min /ml.,Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23938183/),min,171,267722,DB00009,Alteplase
,23938183,AUC,The 1 mg/kg dose yielded the following pharmacokinetic parameters: Cmax = 1.25 ± 0.27 μg/ml; CL = 21.46 ± 5.67 ml/min/kg; dominant half life (t1/2α) = 6.81 ± 1.48 minutes; median elimination half life (t1/2β) = 171 min (range: 85–1061); AUC = 50.33 ± 17.62 μg · min /ml.,Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23938183/),[min·μg] / [ml],50.33,267723,DB00009,Alteplase
,3137685,peak plasma concentrations,Mean peak plasma concentrations at the end of infusion were 4.7 micrograms/ml for hPA(B) and 4.6 micrograms/ml for mtPA.,Clearance of a novel recombinant tissue plasminogen activator in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3137685/),[μg] / [ml],4.7,271301,DB00009,Alteplase
,3137685,peak plasma concentrations,Mean peak plasma concentrations at the end of infusion were 4.7 micrograms/ml for hPA(B) and 4.6 micrograms/ml for mtPA.,Clearance of a novel recombinant tissue plasminogen activator in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3137685/),[μg] / [ml],4.6,271302,DB00009,Alteplase
,3137685,t 1/2 (lambda 1),"The pharmacokinetics of both hPA(B) and mtPA showed a biexponential disappearance from plasma which is consistent with a two-compartment model of t 1/2 (lambda 1) = 2 minutes, t 1/2 (lambda 2) = 58 minutes for hPA(B), and t 1/2 (lambda 1) = 2.2 minutes, t 1/2 (lambda 2) = 61 minutes for mtPA.",Clearance of a novel recombinant tissue plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3137685/),min,2,271303,DB00009,Alteplase
,3137685,t 1/2 (lambda 2),"The pharmacokinetics of both hPA(B) and mtPA showed a biexponential disappearance from plasma which is consistent with a two-compartment model of t 1/2 (lambda 1) = 2 minutes, t 1/2 (lambda 2) = 58 minutes for hPA(B), and t 1/2 (lambda 1) = 2.2 minutes, t 1/2 (lambda 2) = 61 minutes for mtPA.",Clearance of a novel recombinant tissue plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3137685/),min,58,271304,DB00009,Alteplase
,3137685,t 1/2 (lambda 1),"The pharmacokinetics of both hPA(B) and mtPA showed a biexponential disappearance from plasma which is consistent with a two-compartment model of t 1/2 (lambda 1) = 2 minutes, t 1/2 (lambda 2) = 58 minutes for hPA(B), and t 1/2 (lambda 1) = 2.2 minutes, t 1/2 (lambda 2) = 61 minutes for mtPA.",Clearance of a novel recombinant tissue plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3137685/),min,2.2,271305,DB00009,Alteplase
,3137685,t 1/2 (lambda 2),"The pharmacokinetics of both hPA(B) and mtPA showed a biexponential disappearance from plasma which is consistent with a two-compartment model of t 1/2 (lambda 1) = 2 minutes, t 1/2 (lambda 2) = 58 minutes for hPA(B), and t 1/2 (lambda 1) = 2.2 minutes, t 1/2 (lambda 2) = 61 minutes for mtPA.",Clearance of a novel recombinant tissue plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3137685/),min,61,271306,DB00009,Alteplase
